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ABSTRACT
Cytochrome P450 (CYP) enzymes are important enzymes involved in drug metabolism.
The CYP enzymes are a family of heme proteins involved in the metabolism of numerous
toxic and pharmacologically active compounds and can cause drug-drug-interactions with
co-administered drugs as well as unwanted adverse side effects. Several in vitro methods
have been developed and are in widespread use to evaluate main kinetic properties
(absorption, distribution, metabolism, excretion) in drug development projects. These
studies help in identifying molecules that have favourable kinetic properties well before
clinical  studies  in  humans.  The  most  modern  technological  breakthrough  is  the  use  of
computational (in silico) methods to predict kinetic properties of lead molecules.
In the present study, the overall goal was to develop novel in vitro and in silico methods
to  assess  the  metabolic  features  of  xenobiotics.  The  metabolic  focus  of  this  thesis  work  is
inhibition of CYP enzymes. The four aims of the present study were (1) to compare three in
vitro inhibition  screening  tests  for  CYP  enzymes  (2)  to  create  new  inhibition  structure-
activity databases for human CYP enzymes (CYP1A2, CYP2B6, and CYP2E1) (3) to
construct quantitative structure-activity relationship (QSAR) models of inhibitors of these
enzymes and (4) to identify more potent and selective inhibitors for these enzymes.
Three assay types, the traditional single substrate assays, the fluorescent probe method
with recombinant human CYPs, and a novel n-in-one technique, yielded similar results
with the majority of the CYP forms tested. For CYP1A2, CYP2B6 and CYP2E1, new
inhibition structure-activity databases were created, which were large and composed of
structurally diverse compounds. The created quantitative structure-activity relationship
(QSAR)  models  revealed  the  key  molecular  characteristics  of  inhibitors  of  the  CYP1A2,
CYP2B6 and CYP2E1 and were also able to accurately predict inhibitory potencies of the
test set of compounds.  For CYP2B6, three novel potent inhibitors were discovered, 4-(4-
chlorobenzylpyridine) (CBP), 4-benzylpyridine (BP) and 4-(4-nitrobenzylpyridine) (NBP).
In particular CBP is a suitable inhibitor for in vitro screening studies. In vitro high-
throughput screening and in silico studies  can  provide  early  prediction  of  the  possible
involvement of CYP enzymes in the metabolism of drugs or drug candidates. Therefore
these  studies  could  potentially  make  drug  design  more  effective,  less  costly  and  improve
drug safety and replace some of the in vivo experiments.
National Library of Medical Classification: WH 190, QU 143, QU 120, QV 38
Medical  Subject  Headings:  Cytochrome  P450  Enzyme  System;  Drug  Interactions;  Enzyme  Inhibitors;
Xenobiotics/metabolism; Quantitative Structure-Activity Relationship; High-Throughput Screening Assays
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TIIVISTELMÄ
Sytokromi P450-entsyymit (CYP) ovat ihmisen tärkeimpiä lääkeaineita metaboloivia
entsyymejä. Ne ovat ryhmä hemiä sisältäviä proteiineja ja osallistuvat monien toksisten ja
farmakologisesti aktiivisten aineiden metaboliaan, mikä voi aiheuttaa yhteisvaikutuksia ja
ei-toivottuja haittavaikutuksia. Lukuisia in vitro menetelmiä on kehitetty ajan kuluessa ja ne
ovat laajasti käytössä farmakokineettisten ominaisuuksien tutkimuksessa. Näiden
menetelmien avulla saadaan selville ne molekyylit, joilla on sopivat farmakokineettiset
ominaisuudet ennen kuin kliiniset kokeet ihmisellä aloitetaan. Nykyinen teknologinen
edistysaskel on käyttää tietokonemalleja (in silico) näiden ominaisuuksien ennustamiseen.
Tämän väitöstutkimuksen kokonaistavoitteena oli kehittää ja soveltaa uusia in vitro ja in
silico menetelmiä vierasaineiden metabolisten ominaisuuksien tutkimiseen. Tutkimuksessa
keskityttiin mittaamaan, mallintamaan ja ennustamaan vierasainemolekyylien CYP-
välitteisen metabolian inhibitiota.  Väitöskirjatutkimuksen tavoitteena oli: (1) verrata
kolmea CYP-entsyymien inhibiittoreiden in vitro seulontamenetelmää (2) tuottaa rakenne-
aktiivisuus-tietokannat ihmisen CYP-entsyymien (CYP1A2, CYP2B6, CYP2E1)
inhibiittoreista (3) tehdä rakenne-aktiivisuus tietokonemallit näille entsyymeille (4) löytää
in vitro käyttöön uusia CYP-entsyymien inhibiittoreita, jotka ovat voimakkaampia ja
selektiivisempiä kuin tällä hetkellä käytetyt.
Kaikki tutkimuksessa käytetyt seulontamenetelmät: multisubstraattianalyysi,
perinteinen yhden substraatin menetelmä ja 96-kuoppalevymenetelmä fluoresoivilla
substraateilla, antoivat samanlaisia tuloksia muutamia poikkeuksia lukuun ottamatta.
CYP1A2-, CYP2B6- ja CYP2E1-entsyymien inhibiittoreista tuotettiin tietokannat, jotka
sisälsivät suuren määrän rakenteellisesti erilaisia yhdisteitä. Rakenne-aktiivisuus-mallien
avulla saatiin selville inhibiittoreiden tärkeimmät ominaisuudet ja näiden mallien
luetettavuutta testattiin ennustamalla inhibitioarvot molekyyleille, joita ei otettu mukaan
malleihin. CYP2B6-entsyymille löydettiin kolme uutta potenttia inhibiittoria: 4-(4-
klooribentsyylipyridiini) (CBP), 4-bentsyylipyridiini (BP) ja 4-(4-nitrobentsyylipyridiini)
(NBP). Erityisesti CBP on soveltuva inhibiittori in vitro seulontatutkimuksiin. In vitro ja in
silico tutkimukset voivat alustavasti ennustaa CYP-entsyymien osallistumisen uusien
lääkeaineiden metaboliaan. Siksi nämä tutkimukset voivat tehdä lääkekehityksestä
tehokkaampaa, laskea kustannuksia, parantaa lääketurvallisuutta ja korvata joitain in vivo
tutkimuksia.
Luokitus: WH 190, QU 143, QU 120, QV 38
Yleinen suomalainen asiasanasto: sytokromit; entsyymit; inhibiittorit; lääkeaineet; lääkkeet; yhteisvaikutukset;
rakenne; aktiivisuus; vierasaineet; aineenvaihdunta
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1 Introduction
The discovery and development of therapeutically useful drugs requires first an innovative
idea and then expenditure of an enormous amount of labour, money and time. A new
chemical  entity  (NCE)  proceeds from discovery through development  to  registration and
along the way, costs can exceed one billion euro (DiMasi and Grabowski, 2007). One of the
reasons why many clinical drug candidates fail is inappropriate pharmacokinetics. The
studies of absorption, distribution, metabolism, excretion and toxicity (ADMET) of new
drug molecules are carried out today already in the early phase of drug development. The
metabolic  characteristics  of  lead  compounds  need  to  be  scrutinized  to  avoid  drugs  being
withdrawn  from  clinical  studies  or  the  market  due  to  major  kinetic  problems,  such  as
severe interactions related to metabolism. Metabolism of compounds occurs in many
tissues,  with  the  liver  being  the  most  important  organ,  but  also  the  kidneys,  skin,  lungs,
and intestine can metabolize some drugs. Drug metabolism is divided into two types of
reactions, namely phase I (hydrolysis, oxidation, and reduction) and phase II reactions
(conjugation). The metabolism pathway of a drug is mediated by phase I, phase II, or a
combination of both phases.
Cytochrome P450 (CYP) enzymes are a major class of enzymes involved in drug
metabolism. The CYP enzymes are a family of heme proteins participating in the
metabolism of  numerous toxic  and pharmacologically  active  compounds.  The function of
most CYP enzymes is to catalyze the oxidation of xenobiotic substances such as drugs and
other toxic chemicals as well as endogenous compounds e.g. steroid hormones and fatty
acids.  The CYP enzymes biotransform lipophilic  substances  into  more polar  forms which
can then be excreted by the kidneys. About ten CYP forms participate in the metabolism of
xenobiotics  in  humans  with  three  families  being  involved  in  the  majority  of  the  drug
biotransformations; CYP1, CYP2 and CYP3.
Several in vitro methods have been developed and are widely used to detect main
pharmacokinetic properties (ADME: absorption, distribution, metabolism, excretion).
These can help in identifying molecules with favourable pharmacokinetic properties well
before the start of any clinical studies in humans. Nowadays more and more
computational (in silico) methods are being used to predict the kinetic properties of lead
molecules. Rapid advances in several different technologies have yielded increasingly
precise information about the interactions between CYP enzymes and their ligands. In
particular quantitative structure-activity relationship (QSAR), crystal structures of CYP
enzymes and pharmacophore approaches have been used to explore the active sites of CYP
enzymes. These new computational models are promising tools for screening more rapidly
the  quantitative  interactions  between  chemicals  and  CYP  enzymes.  The  methods  used  in
studying  kinetic  properties  can  be  applied  directly  to  other  xenobiotics,  including  the
thousands of chemical compounds to which we are exposed. Thus, these in vitro and in
silico methods are applicable to both drug development and the risk assessment of
chemicals. Studies on the metabolic properties of drugs and chemicals often include in vitro
tests  with  inhibitors  of  individual  CYP  forms.  The  use  of  chemical  inhibitors  is  a  routine
2approach when the relative contribution of CYPs to the metabolism of a particular
compound, e.g. a drug, needs to be evaluated.
Thus the aims of present study were 1) to compare three in vitro inhibition screening
tests for CYP enzymes, 2) to create new inhibition structure-activity databases for human
CYP enzymes (CYP1A2, CYP2B6, and CYP2E1) 3) to construct QSAR models of inhibitors
of these enzymes and 4) to find more potent and selective inhibitors for these enzymes.
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2.1 Drug metabolism
Nowadays evaluation of ADMET (absorption, distribution, metabolism, excretion and
toxicity) properties has become one of the most important issues in drug discovery. In
other words, it is not sufficient that a drug possesses biological activity and therapeutic
efficacy.  If  it  has  undesired  ADMET  properties,  then  this  can  lead  to  failure  during  the
clinical phases. Multiple in silico, in vitro and in vivo ADMET filters are being developed
and implemented at various stages of the drug discovery and development process.
Drug metabolism is divided into two phases: phase I and phase II. In phase I, enzymes
introduce reactive or polar groups into xenobiotics. The common chemical reactions during
this phase are oxidation, reduction, and hydrolysis. The modified compounds are then
conjugated  to  polar  compounds  in  phase  II  reaction.  Phase  II  metabolism  involves  the
introduction of a hydrophilic endogenous species, such as glucuronic acid or sulphate,
onto the drug molecule. Drugs usually first undergo phase I reactions followed by phase II
reactions, but sometimes they can be conjugated without any prior phase I reaction. The
metabolism of drugs into less lipophilic metabolites is essential for their elimination from
the  body.  Metabolism  usually  leads  to  the  inactivation  of  drug,  but  sometimes  the
metabolites are pharmacologically active or even toxic.
2.2 Human cytochrome P450 (CYP) enzyme system
CYP enzymes are the principal drug metabolizing system utilized in phase I metabolism.
CYP enzymes are a multigene family of heme-containing enzyme forms that are involved
in oxidative metabolism of drugs, steroids and carcinogens. They are called P450 because
in the presence of carbon monoxide, the enzymes have an absorption maximum at the
wavelength of 450 nm and P stands for pigment (reviewed by Nebert and Russell, 2002).
This  protein  family  is  commonly  referred  to  as  CYPs,  as  an  abbreviation  for  cytochrome
P450s. In mammalian tissues, CYP enzymes are mainly expressed in the liver, but they are
also located in the intestine, skin, lungs and kidneys. There are two main functional roles
for CYP enzymes: metabolism of xenobiotics and biosynthesis of critical signalling
molecules. There are many members of the CYP superfamily currently known, and the
numbers continue to grow. At present almost 12 000 CYP genes have been identified and
about  sixty  CYP genes  are  reported to  exist  in  the  human genome;  humans have 18  CYP
gene families, and 44 CYP gene subfamilies (Nebert and Russell, 2002; Nelson, 2009). Of
these sixty, it is estimated that more than 90% of human drug oxidation is attributable to
six CYP is enzymes, CYP1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 (Shimada et al. 1994). Some
CYPs are highly regio- and stereospecific in the oxygenation of substrate, whereas others
such as the human liver CYP3A4 metabolize over 50% of the current marketed
pharmaceuticals (Denisov et al. 2005). In other words, a drug can either be a substrate for
4only  one  CYP  enzyme  or  it  can  be  metabolized  by  several  CYP  enzymes.  In  general,  the
substrates for CYP metabolism are hydrophobic and poorly soluble in water. Extensive
lists  of  the  various  substrates  and  corresponding  CYP  systems  involved  have  been
published.  Figure  1  shows  the  most  important  is  forms  participating  in  the
biotransformation of pharmaceutical agents.
Figure 1. Proportion of drugs metabolized by CYP enzymes (modified from Wrighton and
Stevens, 1992)
The primary catalytic function of CYP enzymes is the addition of one oxygen atom from
molecular oxygen (O2) into various substrates and another oxygen atom is further reduced
to water (RH + O2 + NADPH + H+  ROH + NADP+ + H2O, where RH is the substrate). An
external reducing equivalent from NADPH (nicotinamide adenine dinucleotide phosphate)
is required (Lewis, 1998; Guengerich, 2001). The general cycle is presented in Figure 2.
Fe = iron atom in P450 heme, RH = substrate, ROH = product
Figure 2. Generalized CYP catalytic cycle (modified from Guengerich and Johnson, 1997)
5CYP  enzymes  are  grouped  into  families  and  subfamilies.  All  isoenzymes  in  the  same
family have at least 40% and those in the same subfamily at least 55% amino acid
similarities. First the name CYP (indicating P450 enzymes) is followed by an Arabic
number denoting the family, a letter designating the subfamily (when two or more exist),
and  an  Arabic  numeral  representing  the  individual  gene  within  the  subfamily  (Figure  3)
(Nelson et al. 1996).
Figure 3. Nomenclature for the CYP enzymes and allelic forms
In recent years, X-ray crystallography techniques have become a major tool for clarifying
the CYP structure (Wang JF et al. 2009) and an increasing number of crystal structures have
been published in Protein Data Bank (http://www.pdb.org/) (Berman et al. 2000). All of the
CYP crystal structures determined show approximately the same overall mixed alpha–beta
folding. The heme is coordinated by a proximal cysteine and substrates bind in the active
site on the distal side of the heme in the center of the protein. The F and G helices and F/G-
loop with the B/C-loop provide access to the active site of CYPs (Otyepka et al. 2007). The
highly  conserved  parts  of  CYP  structures  are  the  proline-rich  cluster  close  to  the  N-
terminus,  the  loop  following  the  A  helix,  the  C  and  I  helices,  the  proton  transfer  groove,
parts of the K helix and the cysteine pocket (Mestres, 2005; Otyepka et al. 2007; Wang JF et
al. 2009). Many conserved and essential amino acids in the active site of CYP enzymes have
been identified, even though the mechanism of ligand binding is different and their
substrates are diverse (Wade et al. 2005; Mestres, 2005). Lipophilicity relationships,
hydrogen bonding and  stacking interactions are of great concern in substrate
selectivity  and  binding  affinity  along  with  the  volume,  shape  and  the  flexibility  being
determinants of the diversity in recognizing substrates with the stereoselectivity of the
CYPs  being  controlled  by  the  rigid  and  funnel-shaped  access  channel  (Lewis  et  al.  2004;
Kirton et al. 2005; Wang JF et al. 2009).
2.3 CYP1 –family
The  CYP1-family  consists  of  three  members:  CYP1A1,  CYP1A2  and  CYP1B1.  Their
expressions  are  all  regulated  by  the  aromatic  hydrocarbon  receptor  (AHR)  (Nebert  et  al.
2004).  CYP1A1  is  expressed  in  virtually  every  tissue  of  the  body  such  as  the  lung,  skin,
larynx  and  placenta,  and  it  is  known  for  its  capacity  to  activate  compounds  with
carcinogenic properties (Nebert et al. 2000; Androutsopoulos et al. 2009). CYP1A1 is
detected  after  induction  of  polycyclic  aromatic  hydrocarbons  (PAHs).  There  is  also  a
positive association with increased risk of cancer and single nucleotide polymorphisms of
the CYP1A1 (Shi et al. 2008; Varela-Lema et al. 2008; Zhuo et al. 2009; Sergentanis and
6Economopoulos, 2010). CYP1B is the next subfamily in the CYP1-family and it has only one
member, CYP1B1 (Murray et al. 2001). The CYP1B1 gene is also transcriptionally activated
by  PAHs,  with  protein  being  expressed  in  variety  of  human  cancers  and  it  has  been
suggested that CYP1B1 may be a marker of tumorigenesis (Murray et al. 2001). CYP1B1
metabolizes numerous PAHs as well as many N-heterocyclic amines, arylamines, amino
azo dyes, and several other carcinogens (Guengerich, 2000).
2.3.1 CYP1A2
The CYP1A2 enzyme is expressed in the liver and accounts for about 12% of the total CYP
content. The human CYP1A2 gene is PAH-inducible in liver, gastrointestinal tract, nasal
epithelium, and brain (Nebert et al. 2004). Several important drugs e.g. theophylline,
tacrine, clozapine, olanzapine, phenacetin are predominantly metabolized by CYP1A2
(Faber et al. 2005; Pelkonen et al. 2008). CYP1A2 is also important for the metabolism of
endogenous substrates such as melatonin, estrone and estradiol, bilirubin and
uroporphyrinogen (Gunes and Dahl, 2008), and environmental toxins as well as for the
activation of many environmental carcinogens including dietary heterocyclic amines,
certain mycotoxins, tobacco-specific nitrosamines, and aryl amines (Guengerich, 1993;
Eaton et al. 1995). Potent inhibitors of CYP1A2 include furafylline, fluvoxamine,
ciprofloxacin, -naphthoflavone and rofecoxib (Pelkonen et al. 2008; Khojasteh et al. 2011).
Caffeine, phenacetin, melatonin and 7-ethoxyresorufin are the compounds most widely
proposed as good specific probe substrates for use in in vitro testing.
2.4 CYP2 –family
The CYP2 -family is one of the largest and most diverse families which play an important
role in mammalian drug metabolism. The human CYP2A subfamily consists of three genes
and two pseudogenes: CYP2A6, CYP2A7, CYP2A13, CYP2A7P(T) and CYP2A7P(C)
(Fernandez-Salguero and Gonzales, 1995; Honkakoski and Negishi, 1997). CYPs 2C8, 2C9,
2C18 and 2C19 share > 82% amino acid identity, but they only exhibit relatively little
overlap of substrate specificity (Goldstein and de Morais, 1994). CYP2C8, 2C9, and 2C19
proteins are primarily located in the liver, accounting for ~20% of total CYP contents,
whereas CYP2C18 protein seems to be primarily expressed in the skin (Shimada et al. 1994;
Zaphiropoulos, 1997).  Members of the CYP2D family constitute only about 2-4% of total
hepatic CYP content, however, they are responsible for the metabolism of 30% of
commonly prescribed therapeutic compounds.
2.4.1 CYP2A6
In humans, there are three functional genes in the CYP2A subfamily: CYP2A6, CYP2A7 and
CYP2A13.  CYP2A6  is  the  most  important  member:  it  metabolizes  over  30  drugs  from
various therapeutic categories (Rendic, 2002; Rendic and Guengerich, 2010). CYP2A6 is
highly polymorphic and it is expressed in the human liver accounting for about 1-10% of
total CYPs (Koskela et al. 1999; Raunio et al. 2001). CYP2A6 is also recognized for its ability
to metabolize nicotine (Hukkanen et al. 2005) and it is involved in the metabolism of a
number of endogenous substances e.g. contributing to the metabolism of steroids with
7other CYP enzymes and in the metabolic activation of a number of procarcinogens and
environmental compounds (Rendic, 2002; Rendic and Guengerich, 2010). Several
compounds inhibit CYP2A6 and several of them are mechanism-based (suicide) inhibitors
e.g. selegiline (Siu and Tyndale, 2008), methoxsalen (Yoo et al. 2007), and isoniazide (Wen
et al. 2002). The reversible inhibitors include pilocarpine (Kinonen et al. 1995) and
tranylcypromine (Taavitsainen et al.  2001).
2.4.2 CYP2B6
CYP2B6 was thought to be a minor member of the CYP family but recently it has attracted
more interest as its significance in the metabolism of xenobiotics has been appreciated.
CYP2B6 is mainly expressed in the liver and it has been estimated to represent
approximately 1-10% of the total hepatic CYP content (Lang et al. 2001). It can be found
also in various extrahepatic tissues including the kidney, skin, brain, intestine and lung,
and it metabolises over sixty clinically used drugs and a number of procarcinogens and
environmental compounds (Mo et al. 2009b). Some clinically used drugs that are
metabolized by CYP2B6 include cyclophosphamide, tamoxifen, S-mephenytoin, bupropion
and diazepam (Ekins and Wrighton, 1999a; Turpeinen et al. 2006).  Several inhibitors of
CYP2B6 have been described including ticlopidine, clopidogrel, thioTEPA, memantine,
and 2-phenyl-2-(1-piperidinyl)propane (Turpeinen et al. 2006). Clopidogrel, ticlopidine
(Richter et al. 2004), mifepristone (Lin et al. 2009), duloxetine (Paris et al. 2009),
phencyclidine (Shebley et al. 2009) and 17-ethynylestradiol (Kent et al. 2002) are
mechanism-based inhibitors of CYP2B6.
2.4.3 CYP2C8
CYP2C8 accounts for about 7% of total hepatic CYP contents and extrahepatic CYP2C8
mRNA has been detected in numerous tissues including the kidney, intestine, adrenal
gland, brain, mammary gland, ovary, and heart, as well as in breast cancer tumours. It
metabolizes ~5-8% of drugs (Shimada et al. 1994). Its known substrates include paclitaxel
(Rahman et al. 1994), amodiaquine (Li et al. 2002), rosiglitazone (Baldwin et al. 1999) and
its inhibitors are montelukast (Walsky et al. 2005), quercetin (Rahman et al. 1994; Li et al.
2002), gemfibrozil (Wang et al. 2002). CYP2C8 is significantly induced by the prototypical
inducers including rifampicin, phenobarbital, and dexamethasone (Raucy et al. 2002).
2.4.4 CYP2C9
CYP2C9 metabolizes approximately 20% clinical drugs. The majority of CYP2C9 substrates
are acidic compounds such as several nonsteroidal anti-inflammatory drugs e.g. diclofenac
and hypoglycaemic agents (Miners and Birkett, 1998), as well as S-warfarin and phenytoin
(Mo et al. 2009a). This isoenzyme also participates in the oxidation of several important
endogenous compounds such as progesterone, testosterone, 7-ethinylestradiol, all-trans-
retinoic acid and arachidonic acid (Zhou SF, 2009a). Inhibitors of CYP2C9 include
compounds such as sulfaphenazole and benzromarone (Mancy et al. 1996; Takahashi et al.
1999; Locuson et al. 2003) and it is induced by rifampicin and barbiturates (Pelkonen et al.
2008). CYP2C9 is highly polymorphic with more than 33 variants (*1B through to *34) and
a series of subvariants of CYP2C9 have been reported (Wang B et al. 2009). A large
interindividual variation has been noted. The most common allele is named CYP2C9*1,
8and it is considered as the wild-type allele. The variant *2 and *3 alleles are present in
approximately 35% of Caucasian individuals (Lee et al. 2002). CYP2C9*2 was the first
identified and is the most common allelic variant of CYP2C9, but it has a lesser impact on
enzyme activity than CYP2C9*3
2.4.5 CYP2C19
CYP2C19 protein is mainly present in the liver, but significant activity has also been
identified in the gut wall (Obach et al. 2001). CYP2C19 participates in the metabolism of
many commonly used drugs, e.g. citalopram, diazepam, omeprazole, phenobarbital,
proguanil and propranolol (Rendic, 2002). Some proton pump inhibitors like omeprazole
and lansoprazole are inhibitors of CYP2C19 (Ogawa and Echizen, 2010) as are the
antifungal drug fluconazole and antiplatelet drug ticlopidine (Wienkers et al, 1996; Ko et
al, 2000). The most selective inhibitor of CYP2C19 is ()-N-3-benzyl-phenobarbital (Suzuki
et al. 2002; Cai et al. 2004; Khojasteh et al. 2011). 2-4% of Caucasian and 10-25% of Asian
populations are totally deficient in with CYP2C19, CYP2C19*2 and CYP2C19*3 being the
most prevalent (Brockmoller et al. 2000).
2.4.6 CYP2D6
CYP2D6 represent only a few percent of the total human CYP content, but it is estimated to
be involved in the metabolism of approximately 30% of the drugs from a wide variety of
therapeutic indications. CYP2D6 has been identified also in human kidney, intestine,
breast, lung, placenta and brain at low to moderate levels (Zhou SF et al. 2009b). CYP2D6 is
perhaps the most widely recognized polymorphic enzyme. Over 100 allelic variants of
CYP2D6 have been reported, some of which can lead to altered enzyme activity
(http://www.imm.ki.se/CYPalleles). In Caucasians, the phenotypes can be divided into
ultrarapid metabolizers (UMs, 3-5%), extensive metabolizers (EMs, 70-80%), intermediate
metabolizers (IMs, 10-17%) and poor metabolizers (PMs, 5-10%) (Sachse et al. 1997). PMs
may experience increased adverse effects of drugs due to reduced drug clearance rates and
associated elevated drug plasma levels; others may experience reduced effect due to the
inability to activate prodrugs such as codeine (Ingelman-Sundberg, 2005). The typical
substrates for CYP2D6 are usually lipophilic base e.g. some antidepressants,
antipsychotics, antiarrhythmics, antiemetics, ß-adrenoceptor antagonists (ß-blockers) and
opioids (Zhou SF et al. 2009b). Quinidine is most commonly used reference inhibitor
(Khojasteh et al. 2011). CYP2D6 is generally not regulated by many known environmental
agents and is not inducible by the common known enzyme inducers such as steroids (Zhou
SF et al. 2009b).
2.4.7 CYP2E1
The highest levels of CYP2E1 enzyme are present in liver, where its expression
predominates in the zone around the centrilobular vein (Haufroid et al. 2003). To lesser
extent CYP2E1 is expressed also in extrahepatic tissues, such as lung, kidney, nasal
mucosa, bone marrow (Lucas et al. 2001), -cells in pancreas (Murdock et al. 2004), brain
(Lieber, 1999), breast (Kapucuoglu et al. 2003) and heart (Anzenbacher et al. 2001). CYP2E1
is also constitutively expressed in proliferating keratinocytes and epidermal cells (Du et al.
2004) and it can be detected also in the white cell fraction of peripheral blood from
9humans, rabbits and rats (Raucy et al. 1997). CYP2E1 levels vary extensively due, in part, to
pathophysiological conditions (including obesity and diabetes) and the enzyme is
inducible by xenobiotics such as ethanol or volatile organic compounds (Lucas et al. 2001).
CYP2E1 catalyzes the metabolism of wide variety of endogenous substances and
xenobiotics including therapeutic agents, procarcinogens, and low molecular weight
solvents (Haufroid et al. 2003). In general, the majority of compounds are neutral with low
molecular weights and relatively low log P values (Anzenbacher et al. 2001; Lewis et al.
2000; Lewis et al. 2003a; Park and Harris, 2003).  CYP2E1 is mainly responsible for
microsomal ethanol oxidation. Fatty acids are very important endogenous substrates of
CYP2E1 and they are converted preferentially to their (-1)-hydroxylated metabolites
(Adas et al. 1998; Poloyac et al. 2004). The best known CYP2E1 inhibitors include clinically
used drugs, e.g. disulfiram, as well as a herbicide 3-amino-1,2,4-triazole, which is a specific
CYP2E1 inhibitor. Other CYP2E1 inhibitors are dilinoleylphosphatidylcholine (the major
component of polyunsaturated phosphatydilcholines from soy beans) (Aleynik et al. 2001)
and diallylsulphide (which is a mechanism-based inhibitor found in Allium vegetables)
(Loizou and Cocker, 2001).
2.5 CYP3 –family
The  CYP3A  subfamily  of  enzymes  consists  of  four  isoforms;  CYP3A4,  CYP3A5,  CYP3A7
and  CYP3A43.  CYP3A4  is  present  in  the  largest  quantity  of  all  the  CYPs  in  the  liver
(Shimada et al. 1994). CYP3A5 is a minor enzyme, which is expressed in the lungs and
CYP3A7 is the major form of CYP in human fetal liver (Kitada and Kamataki, 1994; Daly,
2006).
2.5.1 CYP3A4
CYP3A4 is expressed predominantly in the liver where it accounts for about 33% of the
hepatic CYP enzyme content. CYP3A4 is the most abundant human hepatic CYP isoform
responsible for the metabolism of almost 50% of known drugs (Wrighton et al. 2000).
Therefore most drug interactions are a result of CYP3A4 inhibition. Among the substrates
of CYP3A4, there are members of several important drug classes: antiarrhythmic agents,
anxiolytics, HIV protease inhibitors, lipid-lowering agents, and strong opioids (Zhou,
2008). CYP3A4 has large active site (~1368 Å3)  which  enables  the  binding  of  multiple
substrates and this might be the cause of atypical kinetics (Korzekwa et al. 1998; Shou et al.
2001; Galetin et al. 2003; Yano et al. 2004).
2.6 Genetic polymorphism of CYPs
The activity of CYP oxidases differs in different people and different populations. The
genetic variation in a population is termed “polymorphism” when two or more clearly
different phenotypes exist in the same population of a species. Polymorphic forms of CYPs
are responsible for the development of a significant number of ADRs (adverse drug
reactions) and 10-20% of all drug therapies are affected by these polymorphisms
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(Pirmohamed and Park, 2003; Ingelman-Sundberg, 2004a). Polymorphisms consist of gene
deletions, gene duplications, single-nucleotide polymorphism (SNPs), and the frame shift
mutations. Four major phenotypes are found:
 The ultrarapid metabolizers (UM), carrying multiple functional genes (greater-than-
normal CYP function)
 The extensive metabolizers (EM), carrying two functional genes (normal CYP
function)
 The intermediate metabolizers (IM), carrying one functional and one defective gene
(intermediate between the poor and extensive metabolizers)
 The poor  metabolizers  (PM),  lacking of  functional  CYP enzymes which may result
from gene deletions or defective genes (little or no CYP function)
All genes encoding CYP enzymes in families 1-3 are polymorphic and these enzymes are
responsible for metabolizing about 40% of all CYP-mediated drugs (Ingelman-Sundberg,
2004a).
2.7 CYP inhibition
Inhibition denotes a decrease in enzyme activity. Determination of CYP inhibition is an
important predictor of potential drug-drug interactions (DDIs). CYP enzyme inhibition can
be either reversible or irreversible, the former being the more common type. Reversible
inhibition is the most common mechanism responsible for documented drug interactions,
competitive inhibition being the most important type.
2.7.1 Reversible inhibition
Reversible inhibition can be divided into competitive, uncompetitive and mixed-type
inhibition (Pelkonen et al. 2008). In competitive inhibition, the binding of the inhibitor
prevents  the  binding  of  the  substrate  to  the  active  site  of  the  enzyme.   An  inhibitor  may
bind to the same binding region or it may partly cover it (Kramer and Tracy, 2008). In
particular when the substrate concentration is low, the inhibition is conspicuous. The
equation for competitive inhibition is shown below.
Eq. 1
v =   [] 	1 + [
] + []
Where v is the observed velocity of the reaction, Vmax the maximum velocity, [S] the
substrate concentration, Km the Michealis-Menten constant, [I] the free inhibitor
concentration and Ki the inhibition constant. When inhibition is competitive, the apparent
Km is increased but the Vmax is not affected by increased inhibitor concentrations.
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In uncompetitive inhibition, the inhibitor does not bind to the free enzyme but instead to
the enzyme-substrate complex and therefore the inhibition increases as the substrate
concentration increases. The equation for uncompetitive inhibition is shown below.
Eq. 2
v =   [] + 	1 + [
]  []
When inhibition is uncompetitive, both the Km and Vmax decrease.
 Non-competitive inhibition is a special case of mixed type inhibition. In non-
competitive inhibition the inhibitor binds not to the active but to another site on the
enzyme and which evokes conformational changes resulting in a reduced metabolic rate
regardless of substrate concentration. The equation for non-competitive inhibition is shown
below.
Eq. 3
v =   [] 	1 + [
] + 	1 + [
]  []
When inhibition is non-competitive, the Vmax is decreased but the Km remains unchanged.
2.7.2 Mechanism-based inhibition
Irreversible inhibition is also called mechanism-based inhibition or suicide inhibition. This
involves the permanent inactivation of enzymes. Irreversible inhibitors are covalently or
noncovalently bound to the target enzyme and dissociate so slowly from the enzyme, that
in effect, the recovery requires resynthesis of the new enzyme molecules. Mechanism-
based inhibitors of CYP enzymes can be classified into two groups, namely irreversible and
quasi-irreversible inhibitors (Kalgutkar et al. 2007; VandenBrink and Isoherranen, 2010). In
the case of quasi-irreversible inhibitors, reactive intermediates coordinate with the heme
prosthetic group leading to the formation of a catalytically inactive metabolite-inhibitor
complex with the CYP enzyme. In irreversible inhibition, reactive intermediates
metabolically generated from the inhibitors covalently react with an active site amino acid
residue within the apoprotein and/or cause direct alkylation/arylation of the heme
destruction (Kalgutkar et al. 2007). There are many experimental compounds that have
been shown to be mechanism-based inhibitors in vitro and several  commonly used drugs
have been described as being mechanism-based inhibitors in vivo (Kalgutkar et al. 2007;
Zhou ZW et al. 2009). Some of the most important mechanism-based inhibitor drugs are
listed in Table 1. Experimentally, irreversible and reversible CYP inhibition can be
differentiated through the examination of the inhibitory concentration (IC50)  at  different
time intervals; for irreversible inhibitors, the IC50 value  changes  over  time,  but  for
reversible inhibitors, the IC50 value remains independent of time.
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Table 1. Drugs that cause drug-drug interactions in humans which are proposed to occur via
mechanism-based inactivation of CYP enzymes (modified from Kalgutkar et al. 2007)
CYP1A2 CYP2D6 CYP2B6 CYP2E1
Enoxacin Paroxetine Clopidogrel Disulfiram
Zileuton Cimetidine ThioTEPA
Furafylline Ticlopidine
CYP2C8 CYP2C9 CYP2C19 CYP3A4
Gemfibrozil (via
glucuronide metabolite)
Tienilic acid Ticlopidine Clarithromycin
Suprofen Diltiazem
Erythromycin
Fluoxetine
Mibefradil
Nefazodone
Nelfinavir
Ritonavir
Saquinavir
Troleandomycin
2.8 Drug-drug interactions
It is very common that the patient needs to be medicated with two or more drugs. Cases of
fatal DDIs have been reported and these have led to the withdrawal of several marketed
drugs or restrictions to their use during the past decades (e.g. cerivastatin, mibefradil,
soruvidine, terfenadine) (Li, 2001). DDIs are usually divided into pharmacokinetic or
pharmacodynamic interactions, or combinations of these two interaction types and all of
these may be involved in these toxic drug interactions. Possible causes of DDIs are
described in Table 2.
Metabolic  interactions  can  be  traced  primarily  to  CYP  enzymes  and  they  are  mainly
based on inhibition or induction of these enzymes. DDI may cause overtreatment and
serious adverse effects by elevating the blood concentration of a drug whose metabolism is
inhibited by the coadministered drug(s). There are many significant DDIs, which have
been known for years. It is an interesting prospect that we can truly predict drug
interactions. In other words, it is crucial to be able to identify those drugs which may
interact with other compounds and to find proper methods to make this identification
before patients suffer the consequences (Zhou ZF et al. 2009). Many of these methods can
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easily predict the type, mechanism and magnitude of interactions, but the clinical
consequences are more complicated to anticipate (Kremers, 2002; Pelkonen et al. 2011).
Table 2. Possible causes of DDIs (modified from Kremers, 2002).
Competition for gastrointestinal absorption
Interaction during membrane crossing (blood vessels, hepatic, renal)
Binding to plasma proteins
Binding to transport proteins and p-glycoproteins
Pharmacodynamic interactions at the receptor level
Inhibition of metabolism
Induction of metabolism
Competition for active renal excretion
2.8.1 Guidelines on the investigation of drug interactions
DDIs are an important issue in clinical practice and drug development. The U.S. Food and
Drug  Administration  (FDA)  first  published  its  guidance  for  drug  interactions  in  1997,
supplemented this information in 1999 and has published additional guidance in 2006,
with a new draft has issued in February 2011. The European Medicines Agency (EMA) also
published guidance in 1995 and recently a new draft has been published (Boobis et al. 2009;
EMA, 2010). According to these guidelines, pharmacokinetic interaction studies should
generally be performed in humans. An in vivo interaction study usually has a cross-over
design and should be performed in healthy adults. A parallel group design is also possible
if the potential inhibitor or inducer has a very long elimination half-life. The in vitro studies
should be conducted before phase I clinical studies and those enzymes involved in
metabolic pathways contributing to  25% of the oral clearance should be verified if
possible in vivo (EMA, 2010).
In the in vitro inhibition studies, the inhibition mechanisms (e.g. reversible or time
dependent inhibition) and inhibition potency (e.g. Ki), are usually investigated using
human  liver  tissues,  e.g.  human  liver  microsomes  or  cDNA-expressed  enzymes  under
linear substrate metabolism and standardized assay conditions. A marker substrate is used
to monitor the enzyme activity and known potent inhibitors should be included as positive
controls in the study. A wide range of concentrations of the investigational drug should be
included in these studies and Ki values  should  be  determined.  FDA  and  EMA  have
recommendations/guidelines about which enzymes should be tested in inhibition studies.
According to FDA it is most important to identify potent inhibitors of CYP3A4 and after
that, inhibitors of CYP2C9, CYP2D6, CYP2C19 and CYP1A2. Furthermore CYP2C8 and
CYP2B6 should also be studied (FDA, 2006; Fowler and Zhang, 2008). EMA has
recommended that in vitro studies  should  be  performed  to  investigate  whether  the
investigational drug inhibits the CYP enzymes most commonly involved in drug
metabolism. These presently include CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19,
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CYP2D6, and CYP3A. It should also be evaluated if time-dependent inhibition is present
(Zhang et al. 2010). In addition, if a metabolite is present in the circulation at molar total or
unbound concentrations (AUC) of at least 1/5 of the concentration of the parent compound,
the metabolites found in vitro should be investigated for their pharmacological activity and
pharmacokinetics. Examples of probe substrates for studying CYP inhibition or induction
effects of the new drug are listed in Table 3 (FDA, 2006; EMA, 2010).
Table 3. Examples of well validated inhibitors and substrates of specific enzyme activities in
vitro (FDA, 2006; EMA, 2010)
Enzyme Inhibitor Substrate
CYP1A2 furafylline (1)(2) phenacetin O-deethylation (1)(2)
CYP2A6 tranylcypromine (2)
methoxsalen (2)
coumarin-7-hydroxylation (2),
nicotine C-oxidation (2)
CYP2B6* ticlopidine (1)(2), thiotepa (1),
clopidogrel (2)
efavirenz hydroxylation (1)(2), bupropion
hydroxylation (1)(2)
CYP2C8 montelukast (1), quercetin paclitaxel 6-hydroxylation (1), amodiaquine N-
deethylation (1), taxol 6-hydroxylation (2)
CYP2C9 sulfaphenazole (1)(2), S-warfarin 7-hydroxylation (1)(2), diclofenac 4´-
hydroxylation (1)(2), tolbutamide methyl-
hydroxylation (2)
CYP2C19* ticlopidine (1)(2),
nootkatone (1)(2), loratadine
(1)
S-mephenytoin 4´-hydroxylation (1)(2)
CYP2D6 quinidine (1)(2) bufuralol 1´-hydroxylation (1)(2), dextromethorphan
O-demethylation (2)
CYP2E1 diethyldithiocarbamate (2)
clomethiazole (2)
diallyldisulfide (2)
chlorzoxazone 6-hydroxylation (2)
CYP3A4 ketoconazole (1)(2),
itraconazole (1)(2)
midazolam 1-hydroxylation itraconazole (1)(2)
testosterone 6-hydroxylation (1)(2)  , plus one
structurally unrelated substance such as nifedipine,
triazolam or dexamethasone (1)(2)
*presently no specific inhibitor known for in vitro use. Listed inhibitor(s) are not specific but can be used
together with other information or in a single enzyme system.
1 EMA 2 FDA
15
2.8.2 Predicting DDIs
Intrinsic  clearance  of  a  drug  forms  the  foundation  for in vitro– in vivo correlations.  It  is  a
measure of enzyme activity toward a drug and is not influenced by protein binding or
hepatic blood flow. The rate of metabolism of a drug is related to the substrate
concentration by the parameter of intrinsic clearance.
Eq. 4Rate of metabolism =   []
Where [S] is the substrate concentration and CLint is the intrinsic clearance.
Traditionally, the method used for estimating the potential of an NCE to inhibit the
activity  of  a  particular  CYP  enzyme  involved  the  generation  of in vitro data  (e.g.  IC50
values) using classical Michaelis-Menten kinetics (Hutzler and Tracy, 2002). The rate of
metabolism can be described by the Michaelis-Menten equation:
Eq. 5
Rate of metabolism =   [] + []
Where  Vmax=maximal velocity, [S]=substrate concentration and Km=concentration of
substrate at which half-maximal velocity is achieved.
A number of factors have to be taken into account in in vitro-in vivo predictions. Only the
unbound  drug  interacts  with  enzymes,  thus  drug  binding  to  protein,  both in vitro and in
vivo, must be taken into consideration (Tracy, 2003; Wienkers and Heath, 2005). There is a
possibility of erroneous results e.g. due to substrate-dependent values. Several types of
atypical kinetic profiles have been observed in drug metabolism reactions. CYP2C9 and
CYP3A4 are the best known for this type of problem. Atypical kinetics include biphasic
kinetics, autoactivation (compound activates its own metabolism), substrate inhibition (the
reaction velocity of product formation decreases once a particular substrate concentration
is surpassed), heteroactivation (enzyme activity for a substrate is increased in the presence
of another compound), partial inhibition (incomplete inhibition is observed even in the
presence of saturating concentrations of a second substrate/inhibitor) and substrate
dependent inhibition (Korzekwa et al. 1998; Hutzler and Tracy, 2002; Kramer and Tracy,
2008). Atypical kinetics have been characterised more extensively in vitro than in vivo and
that raises a question about the choice of in vivo probe drugs (Wienkers and Heath, 2005).
Extrapolations from in vitro to in vivo have been made and the qualitatively more potent
inhibitors in vitro tend  to  be  those  drugs  that  cause  DDIs in vivo, but potency alone is in
itself not quantitatively predictive (Obach et al. 2005).
Polymorphic expression of several CYP enzymes introduces another stumbling block
into investigations of DDIs. CYP2D6 is by far the best characterized CYP enzyme that
demonstrates polymorphic  expression  in  humans  (Linder  et  al.  1997).  The  polymorphism
of the CYP2D6 enzyme results in poor, intermediate, efficient or ultrarapid metabolizers of
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drugs (Ingelman-Sundberg, 2005). When compared to reversible inhibition in which the
magnitude  of  the  DDI  diminishes  as  the  inhibitor  is  cleared  from  the  body,  mechanism-
based inhibitors of CYP enzymes cause more often unfavourable DDIs, since the
inactivated CYP enzymes have to be replaced by newly synthesized proteins (Kalgutkar et
al. 2007; Zhou ZF et al. 2009). This can take a longer time compared to the rate at which the
inhibitor is eliminated. For example, 14 out of 19 identified clinically significant CYP3A4
inhibitors are either established or putative mechanism-based inactivators of the enzyme.
2.8.3 Methods in CYP-mediated DDI research
CYP inhibition assays typically consist of an incubation mixture of fixed concentration of
the test compound (inhibitor), recombinant CYP enzymes or human liver microsomes and
a probe substrate which is metabolized to a product that can be measured (figure 4)
(Wienkers and Heath, 2005). The potency of inhibition can be assessed by the
determination of the Ki or IC50 values. The half maximal inhibitory concentration (IC50) is a
measure  of  the  effectiveness  of  a  compound  in  inhibiting  biological  or  biochemical
function; it represents the concentration of a drug that is required for 50% inhibition in
vitro. Ki is  the  inhibition  constant  for  a  drug.  An  IC50 is determined at a single substrate
concentration with multiple inhibitor concentrations whereas assessment of the Ki value
demands multiple substrate concentrations with multiple inhibitor concentrations. Thus
the IC50 value is enzyme- and substrate concentration-dependent unlike the Ki (Kramer and
Tracy, 2008). A general relationship between IC50 and Ki, where [S] is the concentration of
substrate used in vitro IC50 determination, can be summarized as follows (Wienkers and
Heath, 2005):
Eq. 6
IC50 = Ki  1 + [S]Km
The apparent IC50 value approximately equals 2*Ki, when IC50 values are determined under
adequate conditions with relevant probe substrates at a concentration near to the Km values
for competitive or uncompetitive inhibitors. For a noncompetitive inhibitor, the IC50 value
is closer to Ki (Bjornsson et al. 2003; Bell et al. 2008).
Figure 4. A typical in vitro CYP inhibition assay (modified from Wienkers and Heath, 2005)
Test compound
(inhibitor)
+microsomes
or rhCYP
+probe
substrate
+co-factor
(NADPH)
Measure
product
formation
(fluorescence
or LC-MS)
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2.8.3.1 In vitro techniques
Fluorometric assays represent the most common approach used to test compounds as CYP
inhibitors  in  early  drug  discovery  and  the  use  of  recombinant  CYP  enzymes  with
fluorescent  probes  (substrates)  gives  the  highest  throughput  levels  when  compared  to
other possibilities (Wienkers and Heath, 2005; Foti et al. 2010).  In this method, a pro-
fluorescent substrate is metabolized into fluorescent products which are then detected by a
fluorometer. Substrates have been developed particularly to form fluorescent products, but
they mostly are not specific for any CYP form (Bjornsson et al. 2003). They are easy to use
and  generally  provide  a  high  level  of  reproducibility;  speed  and  low  cost  are  other
advantages (Miller et al 2000; Crespi et al. 2002; Trubetskoy et al. 2005, Wienkers and
Heath, 2005). The drawbacks of this method are disturbance due to test inhibitors which
can cause fluorescence quenching or fluoresce itself; despite the fact these are not very
common (Fowler and Zhang, 2008).
It might be practical to use a fluorescence method for the robust screening and further or
detailed assays LC-MS method, but there is not always a good agreement between these
two methods (Bell et al. 2008; Wang, 2009). For example, the IC50 value is not constant
within a particular CYP enzyme, being completely substrate-dependent. LC-MS has
become the standard measurement technology for in vitro DDI experiments (Fowler and
Zhang, 2008). This approach offers some advantages over fluorometric assays e.g.
simultaneous evaluation of CYP isoform activities, the high selectivity of probe substrates
for their respective CYP enzymes and the use of clinically relevant probe substrates.
There are many variables which need to be taken into account in measuring CYP
inhibition potency. The choice of buffer strength and pH, divalent metals and organic
solvents can all have effects on the outcome of in vitro drug interaction studies. The
substrate concentration should be chosen where CYP catalysis follows Michaelis-Menten
kinetics  and  it  is  usually  equal  to  its  apparent  Km  for  the  given  CYP  enzyme  (Wienkers
and Heath, 2005). In addition, preferably less than 20% of the substrate should be
consumed during the assay. The incubations should be performed using conditions where
linearity can be assured with respect to time and enzyme concentration. In particular many
early lead compounds are highly lipophilic causing solubility problems. The concentration
of organic solvent must be as low as possible due to potential inhibitory effects (e.g. <0.5%
final (v/v)), but this may cause precipitation of the inhibitor (or the substrate). The test
inhibitor might be metabolized and there is the possibility that the metabolites can be more
potent inhibitors than the parent substance. It is also advisable to use the lowest possible
amount protein in the incubation (below 0.5 mg of microsomal protein · ml -1 is suggested)
in order to avoid protein binding (Bjornsson et al. 2003). In some cases, the inhibitory
potency may depend on the substrate. This is best known with CYP3A4 (Kenworthy et al.
1999). One explanation is that CYP3A4 has three different binding sites or the binding site
is  sufficiently  large  to  allow  multiple  substrates  to  bind.  It  is  recommended  that  two
substrates are used with this enzyme (Houston and Kenworthy, 2000).
Expressed CYP enzymes
Nowadays many manufacturers have commercially available cDNA-expressed CYP
enzymes. The specific enzyme is usually expressed in either baculovirus-insect cell
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expressed human enzymes or an E. coli –based expression system, allowing for a virtually
inexhaustible supply of reagents.  There is only a single CYP enzyme present,  so the need
for a highly selective probe substrate is not essential (Foti et al. 2010). Recombinant
enzymes are valuable in high throughput screening (HTS), they can be used with HTS
substrates and the role of individual CYPs is easily studied in the metabolism of an NCE
(Raunio et al. 2004; Pelkonen et al. 2005). The disadvantage of expressed microsomal CYPs
is that only a single enzyme at a time can be studied and the metabolic contribution of
other enzymes is not represented (Raunio et al. 2004; Pelkonen et al. 2005; Kramer and
Tracy, 2008).
Human liver microsomes
Human liver  microsomes are  also  very convenient,  low in  cost  and easy to  use.  They are
extremely popular and a widely used in vitro system  for  studying  CYP  kinetics  (Kramer
and Tracy, 2008). They contain a more complete complement of hepatic drug metabolizing
enzymes  when  compared  to  recombinant  enzymes  and  thus  represent  a  more
physiologically relevant system in which to evaluate CYP inhibition (Foti et al. 2010). Liver
microsomes consist of vesicles of the hepatocyte endoplasmic reticulum and are prepared
by differential centrifugation. The selectivity of probe substrates for a particular CYP
isoform is more important when multiple CYP enzymes are being evaluated
simultaneously (Wienkers and Heath, 2005). The disadvantage is the incomplete
representation of the in vivo situation, because only CYP and UGT enzymes are represent
(Brandon et al. 2003).
Hepatocytes
Hepatocytes can also be used to assess drug interactions, but they are less commonly used
for studies of human enzymes, because they are relatively difficult to obtain and difficult to
preserve  for  later  use.  They  are  highly  differentiated  cells  and  do  not  normally  divide  in
culture (Boobis et al. 2009). They should be the most representative of the situation
occurring  in  vivo,  because  they  contain  the  full  complement  of  phase  I  and  phase  II
enzymes. The inhibition potential of compounds in hepatocytes versus human liver
microsomes has assessed to display in good agreement between the two techniques
(Brown et al. 2007).
Human liver S9 fractions
Liver S9 fractions are subcellular fractions that contain drug-metabolizing enzymes
including the CYPs, flavin monooxygenases, and UDP-glucuronyltransferases. It is a major
advantage that they contain both phase I and phase II activity. One disadvantage is the
overall lower enzyme activity, 20-24 lower enzyme activity than in microsomes and
expressed enzymes (Brandon et al. 2003; Kramer and Tracy, 2008).
Liver slices
Liver slices resemble most closely the in vivo environment, because they contain the entire
complement of metabolizing enzymes and all cell types from the organ tissue and all the
connections between the cells are present (Lerche-Langrand and Toutain, 2000; Kramer
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and Tracy, 2008). Unfortunately liver slices are relatively difficult to obtain and the
maintenance is demanding. In addition, loss of CYP catalytic activity is can occur, thus
metabolism studies are best performed using freshly cut slices (VandenBranden et al. 1998;
Kramer and Tracy, 2008).
2.8.3.2 In silico techniques
In silico is an expression used to mean "performed on computer or via computer
simulation."  The chemical  space  of  drug-like  compounds is  too large  to  screen by in vitro
tests and the amount of synthesized drug is low and syntheses are slow. Thus there is an
increasing demand for  computational  tools  that  can identify  and analyze active  sites  and
identify molecules that can bind to the active sites. Computational approaches can be
roughly divided into two main categories: ligand-based approaches and structure-based
(protein-based) approaches (de Graaf et al. 2005; Arimoto, 2006; de Groot, 2006). Ligand-
based approaches include pharmacophore modelling, quantitative structure-activity
relationship (QSAR), three-dimensional (3D) QSAR and similarity searches (Wang JF et al.
2009). All of these models provide indirect information about a protein´s active site
without  prior  knowledge  about  the  protein  structure.  These  models  are  based  on  the
shape, electronic properties and conformations of substrates, inhibitors or metabolic
products and they use experimental data (de Groot et al. 2006).
In structure-based drug design, the three-dimensional structure of a drug target
interacting with molecules is used (figure 5). Structure-based approaches include
homology modelling, docking and molecular dynamic simulations; these provide direct
structural information of the target proteins (Wang JF et al. 2009). If the shape and chemical
nature of the binding site are known and the interactions between ligands and the protein
within its active site have been identified, this can be applied for the identification of new
ligands and optimization of lead compounds. In that case, so-called hits can be identified
through the docking of molecules into the active site (Andricopulo et al. 2009). Molecular
docking is a technique for predicting whether a small molecule, ligand, will bind to a host
macromolecule, typically to a protein. It is done by predicting energetically favourable
binding conformations and orientations of the molecules within the active site of target
protein and modelling the interaction between the protein and a ligand. The ligand will
potentially bind to the protein in vitro or in vivo if the geometry of the ligand-protein pair is
complimentary and involves favourable biochemical interactions. With cytochrome P450s,
the  most  common  docking  algorithms  applied  include  GOLD,  FlexX,  DOCK  and
AutoDock (reviewed by de Graaf et al. 2005).
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Figure 5. The principal steps in structure-based drug design using crystallography (modified
from Neidle and Thurston, 2005)
2.8.3.3 Quantitative structure-activity relationship
QSAR is a mathematical and statistical model that tries to detect relationships between the
molecular properties of molecules and biological activity. Lipophilicity, polarizability,
electric properties and steric parameters are used to describe different size of substituents.
This  method  has  been  known  for  almost  50  years  and  it  was  first  introduced  by  Hansch
and Fujita in 1964. It is often run in parallel with homology modelling to enable
interpretation and understanding of the active site through superimposition of a set of
structurally different compounds (Chohan et al. 2006). QSAR studies use supervised
methods often classified into the following categories: linear methods such as multiple
linear regression (MLR), principal components regression/analysis (PCR/PCA), partial least
squares (PLS) and non-linear methods such as artificial and Bayesian neural networks
(ANN and BNN) and classification and regression trees (CART) (Chohan et al. 2006;
Verma et al. 2010). Developing a good quality QSAR model depends on many factors, such
as the quality and accuracy of biological data, the choice of descriptors and statistical
methods. Although there are many problems with QSAR and sometimes they fail, QSAR
does possess several advantages. Conventional synthetic methods and biological assays are
expensive and time-consuming and may require the use of animals. Even more serious,
drug failures due to poor ADMET profiles at later stages of development are extremely
expensive and thus estimations are needed to allow prioritization of synthesis and
screening (Verma et al. 2010). 3D-QSAR refers to the application of force field calculations
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requiring three-dimensional structures, e.g. based on protein crystallography or molecule
superimposition.
CoMFA
Cramer and co-workers published a method called comparative molecular field analysis
(CoMFA) in 1988 (Cramer et al. 1988). This method is an advanced QSAR analysis which
correlates the property fields of sets of molecules (steric and electrostatic fields) with their
activity  (e.g.  IC50 value).  CoMFA  is  the  most  widely  used  3D  QSAR  approach  for  the
prediction of biological activity (Andricopulo et al. 2009). In CoMFA, a set of molecules is
needed and those molecules should interact in the same manner with the same kind of
receptor. Molecules are subdivided into a training and a test set: the training set molecules
are diverse with respect to binding affinity and structural features and the properties of the
molecules  in  the  test  set  are  similar  to  those  of  the  training  set.  The  crucial  step  in
constructing a CoMFA model is the alignment of the training set molecules. This has a
major impact on the outcome of the 3D statistical analysis (Andricopulo et al. 2009). The
interaction energies are calculated using probes such as small molecule like water or a
chemical fragment such as a methyl group (Verma et al. 2010). Interactions are represented
by the standard potential energy fields in which the differences are related to differences in
biological activity.
Relationships between the interaction fields and biological activity are calculated using
Partial Least Square (PLS) (Cramer et al. 1998). PLS models are validated to ensure the
quality and predictive power of the model. The validation of the model is done by Leave-
one-out cross-validation-method or Standard leave-some-out cross-validation method. The
first calculates as many models as there are compounds in the data set, and then leaves
each compound out of the model and predicts its activity. The latter technique divides the
compounds into a specified number of groups leaving each one out, one at a time. Most
often  the  results  are  presented  as  a  3D  coefficient  contour  map,  which  shows  the
favourable and unfavourable steric regions around the molecules and the favourable and
unfavourable regions for electropositive or electronegative substituents in certain positions
(Höltje, 2003).
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3 Aims of the study
The general objective of this study was to develop novel in vitro and in silico methods  to
assess the metabolic features of xenobiotics. The metabolic feature covered in this thesis
work is inhibition of CYP enzymes. The specific aims were as follows:
1. To compare three CYP in vitro inhibition screening tests
2. To create new inhibition structure-activity databases for human CYP enzymes
(1A2, 2B6, 2E1)
3. To construct QSAR models of inhibitors of selected CYP enzymes
4. To identify more potent and selective inhibitors of CYP enzymes.
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4 General experimental procedures
4.1 Materials
4.1.1 Chemicals
Fluoxetine  was  a  kind  gift  from  Solvay  Pharma  (Brussels,  Belgium).  Sotalol,  propranolol,
citalopram, oxazepam, diazepam, -heptalactone, -caprolactone, -decanolactone, -
dodecanolactone, -caprolactone, 4,6-dimethyl--pyrone, 1,3-dimethylnaphthalene, 1,4-
dimethylnaphthalene, 4-methoxybenzaldehyde, 1-naphthol, nicotine, cotinine and 7-
ethoxyresorufin were obtained from Sigma Chemical Company (St. Louis, MO). Bupropion
and hydroxybupropion were generous donations from Glaxo SmithKline (Research
Triangle, NC), midazolam and -hydroxymidazolam from F. Hoffmann-La Roche (Basel,
Switzerland) and omeprazole, omeprazole sulphone and 5-hydroxyomeprazole from Astra
Zeneca (Mölndal, Sweden). The metabolite standards dextromethorphan, 6-hydroxychlor-
zoxazone, hydroxytolbutamide and 6-hydroxytestosterone were purchased from
Ultrafine Chemical Company (Manchester, U.K.). Formic acid, LichroSolv GG methanol
and acetonitrile were obtained from Merck KGaA (Darmstadt, Germany). Undecanoic--
lactone, -valerolactone, -decanolactone, -phenyl--butyrolactone, (+/-)-undecaonic--
lactone, -nonanoic-lactone, 2,3-dihydrobenzofuran, 4-methoxyfuran2(5H)-one, 2-
benzoxazolinone, butylbenzyl, 2-indanone, 2-coumarone, indan, butylcyclohexane, 2,7-di-
methylnaphthalene, 2-methoxynaphthalene, 2-(p-tolyl)ethylamine, 1-methylnaphthalene,
quinaldine, 2-ethylnaphthalene, 1,5-dimethylnaphthalene, 2,6-dimethylquinoline, 2-
methylnaphthalene, 1,6-dimethylnaphthalene, 3-methylisoquinoline, 2,6-dimethylnaphtha-
lene, 2,7-dimethylquinoline, 3-methylquinoline, 1,2-dimethylnaphthalene, 2,4-
dimethylquinoline, 2-naphthol and naphthalene, 4-(4-chlorobenzyl)pyridine (CBP), 4-ben-
zylpyridine (BP), 2-benzylaniline, 4-hydroxydiphenylmethane, 4-chlorobenzophenone, 3,4-
dihydroxybenzaldehyde and 2-(4-aminophenyl)-ethanol were purchased from Aldrich-
Chemie GmbH & Co. (Heidenheim, Germany). Biphenyl and 1,7-dimethylnaphthalene
were purchased from Fluka Chemie AG (Buchs, Switzerland). 2-Chlorobiphenyl, 4-
chlorobiphenyl, 1,4-dichloronaphthalene, 1,5-dichloronaphthalene and 1-chloronaphtha-
lene were from Promochem (Boras, Sweden). 4-Benzoylpyridine, 4-(4-chloroben-
zoyl)pyridine,  4-(4-nitrobenzyl)pyridine (NBP), 4,4-DDM, bromodiphenylmethane, 4-
bromo-benzaldehyde, 4-hydroxybenzophenone, 4-bromobenzylbromide, 4-
hydroxybenzaldehyde, were purchased from Acros Organics (New Jersey, USA). 2-
Fluoronaphthalene  was  from  Supelco  (St.  Louis,  MO,  U.S.A.).  NADP  was  from  Roche
Diagnostic GmbH (Mannheim, Germany). All other chemicals used were from Sigma
Chemical Company (St. Louis, MO) and Boehringer (Ingelheim, Germany) and were of the
highest purity available. Water was in-house freshly prepared with Simplicity 185 (Milli-
pore S.A., Molsheim, France) water purification system and was UP grade (ultra pure, 18.2
M).
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4.1.2 Biological material
4.1.2.1 Human liver microsomes
The human liver samples used in this study were obtained from the University Hospital of
Oulu as a surplus from transplantation donors. The collection of surplus tissue was
approved by the Ethics Committee of the Medical Faculty of the University of Oulu,
Finland. The livers were transferred to ice immediately after surgical excision, cut into
pieces, snap-frozen in liquid nitrogen and stored at -80 C until the microsomes were
prepared by standard differential ultracentrifugation. A weight-balanced microsomal pool
of seven liver microsomal preparations which have been extensively characterized for
primary screening (sufficient model activities, no known polymorphisms, expected effects
of model inhibitors, quantification of CYPs by Western blotting) was employed. The final
microsomal pellet was suspended in 100 mM phosphate buffer pH 7.4. The protein content
was determined by the method of Bradford (1976).
4.1.2.2 cDNA expressed human P450s
Baculovirus-insect cell expressed human CYP enzymes were purchased from BD
Biosciences Discovery Labware (Bedford, MA) and used according to the manufacturer’s
instructions.
4.2 Methods
4.2.1 Fluorescent probe assays
Incubations were performed in 96-well plates. The experimental conditions are
summarized in Table 4. In each well, the 150 μl incubation volume contained 100 mM Tris-
HCl  buffer  (pH  7.4),  4.2  mM  MgCl2, 1-100 μM substrate and cDNA expressed CYP. The
reaction was initiated by adding the NADPH-generating system after 10 min preincubation
at 37 °C.  After a given incubation time the reactions were terminated by the addition of
110 μl 80% acetonitrile / 20% 0.5 M Tris Base. For CYP2A6 in each well, a 100 μl incubation
volume  contained  50  mM  Tris-HCl  buffer  (pH  7.4)  and  5.0  mM  MgCl2. The reaction was
initiated by addition of NADPH and terminated by adding 60 μl 10% TCA. Immediately
before the measurement 140 μl 1.6 M glycine-NaOH buffer (pH 10.4) was added. For
CYP2C8, the reaction was terminated by 2 M NaOH. The formed fluorescence was
measured with a Victor2 plate counter (Perkin Elmer Life Sciences Wallac, Turku, Finland).
For assays using DBF, the signal to noise ratio was greatly increased when the plate was
incubated (37 °C) approximately two hours after the addition of NaOH. The linearity of the
reaction with respect to incubation time and protein concentration was determined.
Several  control  incubations  were  carried  out  to  determine  the  effect  of  quenching  by  the
inhibitors and other interfering factors. All IC50 values were determined in duplicate. The
IC50 values were calculated using non-linear regression analysis with Prism 4.0TM software
(San Diego, California, U.S.A.) from the results of two separate experiments.
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Table 4. Experimental  conditions  of  fluorescent  probe  assays  in  recombinant  human  CYP
enzymes
CYP isoform
Substrate and
concentration (μM)
Fluorescent
metabolite
Incubation
time (min) Enzyme (pmol)
1A2 7-ethoxyresorufin (1) Resorufin 20 0.5
2A6 Coumarin (3) 7-Hydroxycoumarin 15 0.75
2B6 EFC (2.5) HFC 30 0.75
2C8 DBF (1) Fluorescein 30 3
2C9 MFC (75) HFC 45 0.75
2C19 BFC (25) HFC 45 2.5
2D6 MAMC (7.5) HAMC 60 1.5
2E1 MFC (100)(10)* HFC 45, 45* 1.5, 0.5*
3A4 BFC (50) HFC 30 0.75
* Used in Chapter 8
4.2.2 Comparative Molecular Field Analysis (CoMFA)
CoMFA is a ligand-based predictive software with the ability to derive three-dimensional
quantitative structure-activity relationships (3D-QSARs). Using regression analysis on the
charges for each atom of each molecule in a 3D aligned library, CoMFA can correlate
electrostatic and steric properties with activities (e.g. IC50 values) obtained by biological
experiments. Two utilities of CoMFA analysis are its use as a predictive tool to predict IC50s
(or  other  properties)  of  other  ligands  and  contour  plots  that  allow  the  visualization  of
predicted favourable and unfavourable properties of the ligands in 3D. Generally, these
plots can be directly translated to interactions with the enzyme, allowing a more directed
route of ligand design that exploits the desired properties (Cramer et al. 1988).
The construction of the molecules, superimposition and CoMFA modelling were
performed  using  the  Sybyl  6.9  (TRIPOS  Associates  Inc.,  St.  Louis,  MO)  molecular
modelling software (Clark et al. 1989). The biological data was transformed to pIC50 (-
logIC50) values. Atomic point charges were calculated using the MMFF94 method (Halgren,
1996). Standard CoMFA analysis included steric and electrostatic fields which were
calculated using the sp3 carbon probe atom with a +1 charge and a 2 Å grid spacing. The
standard derivation threshold for exclusion of columns from the PLS analysis was set at 2
kcal/mol. The PLS method with 5 random group cross-validations was used for statistical
analyses and this calculation was repeated 20 times to verify the stability of the obtained q2
values. The optimum number of components for the non-validated analyses was chosen
according to the validation results: concerning the lowest SPRESS (standard error of
prediction) or SDEP0* (corresponding value from progressive scrambling), highest q2 or
Q0*2 (corresponding value from progressive scrambling). The predictive capacity of the
generated model was tested using an external set of compounds.
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5 Comparison of cytochrome P450 inhibition screening
tests 1
Abstract: There are several different experimental systems for screening of in vitro
inhibitory potency of drugs under development. In this study we compared three different
types of cytochrome P450 (CYP) inhibition tests: the traditional single substrate assays, the
fluorescent probe method with recombinant human CYPs, and a novel n-in-one technique.
All major hepatic drug-metabolizing CYPs were included (1A2, 2A6, 2B6, 2C8, 2C9, 2C19,
2D6, 2E1, 3A4). Six compounds (sotalol, propranolol, citalopram, fluoxetine, oxazepam and
diazepam) were selected for detailed comparisons. The IC50 values  of  each  of  these
compounds were measured using the three assay types. The inhibitory potencies of these
model drugs were generally within the same order of magnitude and followed similar
inhibition profiles in all the assay types. Clinically observed inhibitory interactions, or lack
thereof, were predictable with all three assays. Comparison of potencies of ‘diagnostic’
inhibitors revealed also some notable differences between the assays, especially regarding
CYP2E1. The potency of inhibitors towards CYP3A4 was dependent on the substrate and
reaction measured.  Generally all three assays gave reasonably comparable results,
although some unexplained differences were also noted.
1 Adapted with permission of Elsevier LTD from: Turpeinen M, Korhonen LE, Tolonen A, Uusitalo J, Juvonen R,
Raunio H and Pelkonen O. Cytochrome P450 (CYP) inhibition screening: comparison of tests. Eur J Pharm Scien. 29:
130–138, 2006
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5.1 Introduction
Metabolism tests most suitable for high throughput screening usually include metabolic
stability and drug interaction (CYP inhibition) assays (Li et al. 2001; White, 2000), and also
more elaborate test systems are available. However, none of the in vitro systems currently
available for drug metabolism is yet validated and comprehensive controlled data bases
are rare or include only a modest number of drugs (Pelkonen and Raunio 2005; Pelkonen et
al. 2005; Hutzler et al. 2005).
The aim of this work was to systematically compare the performance of three basic types
of in vitro metabolism inhibition tests. These tests are 1) a conventional single substrate
assay, 2) fluorescence based technology and 3) a newer, n-in-1 technique, all developed for
measuring the inhibition of major drug-metabolizing cytochrome P450 (CYP) activities. Six
compounds (sotalol, propranolol, citalopram, fluoxetine, oxazepam and diazepam) from
three different therapy classes (	-adrenergic receptor antagonists, selective serotonin
reuptake inhibitors and benzodiazepines) were selected on the basis of previous literature
reports on their CYP inhibition potential. Each compound pair represents drugs with
different inhibition profiles.
5.2 Materials and methods
The materials and general methods (fluorescent probe assay) used are described in Chapter
4.
5.2.1 Single substrate assays
The incubation conditions and instrumentation used to assess the enzyme activities of
CYP1A1/2 (ethoxyresorufin O-deethylation), CYP2A6 (coumarin 7-hydroxylation),
CYP2C9 (tolbutamide hydroxylation), CYP2D6 (dextromethorphan O-demethylation),
CYP2E1 (chlorzoxazone 6-hydroxylation), CYP3A4/5 (midazolam 1´-hydroxylation) have
been described previously in detail in Taavitsainen et al. (2001) and the assay for CYP2B6
(bupropion hydroxylation) in Turpeinen et al. (2004). Each reaction mixture was
preincubated for 2 minutes at +37 C in a shaking incubator block (Eppendorf
Thermomixer 5436, Hamburg, Germany). The reaction was started by adding NADPH and
terminated by adding equal volume of ice-cold acetonitrile and subsequently cooled in an
ice bath to precipitate the proteins. The mixture was vortex mixed and spun at 10,000g for
15 minutes. Supernatants were collected and stored at -20 C until analyzed.
The amodiaquine N-deethylation assay for CYP2C8 was a modification from Li et al.
(2002): incubation mixtures contained 0.5 mg protein/ml and 30 μM amodiaquine and the
incubation time was 20 min. Omeprazole 5-hydroxylation and sulphoxidation assays for
CYP2C19 and CYP3A4, respectively, were adapted from Äbelö et al (2000): incubation
mixtures contained 0.5 mg microsomal protein /ml and 40 μM omeprazole and incubation
period was 20 min. Otherwise the incubations contained buffer and NADPH and were
performed as described above.
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5.2.2 N-in-one assay
Conduction of the n-in-one assay was described previously in detail in Turpeinen et al.
(2005). Shortly, each incubation mixture contained 0.5 mg microsomal protein/ml, 0.1 M
phosphate buffer (pH 7.4), 1 mM NADPH and all the ten probe substrates. Substrates and
their concentrations for the incubations were: melatonin (0.4 mM),  coumarin (0.2 mM),
bupropion (0.1 mM), amodiaquine (0.2 mM), tolbutamide (0.4 mM), omeprazole (0.2 mM),
dextromethorphan (0.02 mM), chlorzoxazone (0.6 mM), midazolam (0.04 mM) and
testosterone (0.1 mM). Reaction mixture, in a final volume of 200 μl, was preincubated for 2
minutes at +37 C in a shaking incubator block (Eppendorf Thermomixer 5436, Hamburg,
Germany) before the reaction was initiated by addition of NADPH. Each reaction was
terminated after 30 minutes by adding 100 μl of ice-cold acetonitrile containing warfarin
(1.5 μM) as an internal standard (ISTD). Samples were subsequently cooled in an ice bath
to precipitate the proteins. Supernatants were collected into clean tubes and stored at -20
C until analyzed. For analysis all incubation samples were thawed at room temperature,
shaken and centrifuged for 10 min at 10,000*g. The supernatants were transferred to a
Waters Total Recovery vial (Waters Corporation, Milford, Massachusetts, USA) to await
LC/TOF-MS analysis.
5.2.3 HPLC conditions
A Waters Alliance 2695 chromatographic system with autosampler, vacuum degasser and
column oven was used. The analytical column was a Waters XTerra MS C18, 2.1*50 mm,
3.5 
m with Phenomenex Luna C18(2) precolumn, 4.0*2.0 mm, 3.0 
m (Phenomenex,
Torrance, California, USA). The flow rate was 0.3 ml/min and the column oven
temperature was 30 ºC. The eluents used were A: aqueous 0.1% formic acid (pH 2.75) and
B: methanol. Gradient elution from 15% B to 60% B in 10 min was used. The flow was split
post-column with Acurate Post-Column Stream Splitter (LC Packings, Amsterdam, The
Netherlands). The split ratio was 1:4 to MS and waste, respectively.
5.2.4 LC/ESI/MS conditions
LC/MS data were recorded with a Micromass LCT time-of-flight (TOF) high resolution
mass spectrometer (Micromass Ltd., Manchester, England) equipped with Z-Spray
electrospray ionization source. A generic positive electrospray ionization method was used
for all substrates and metabolites including internal standard. Basic parameter conditions
were capillary, sample cone and extraction cone voltages 3000, 20 and 3 V, desolvation and
nebulization N2 flows 600 and 70 l/h, and desolvation and source temperatures 220 and 150
C, respectively. The mass spectrometer and HPLC system were operated under
Micromass MassLynx 3.4 software, which also was used to process the measured LC/MS
data. Chromatographic traces of protonated metabolites of CYP specific substrates were
extracted from total ion chromatograms or traces of appropriate molecular ions
(protonated and/or Na+ or  K+-adducts) and/or in-source fragments were combined. Mass
chromatograms were then integrated and peak areas were normalized to ISTD. No
quantification was performed. The peak areas of metabolites in different incubations were
compared as such after internal standard corrections were made. The standard deviations
of warfarin (ISTD) peak areas were typically below 10%.
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5.2.5 In vitro inhibition and reference inhibitors
For determinations of the IC50 values the study compounds were added into the incubation
mixture in five different concentrations (0.01, 0.1, 1, 10 and 100 μM) in a small volume of an
appropriate solvent. The solvents used were water (sotalol and citalopram), methanol
(diazepam) and DMSO (propranolol, fluoxetine and oxazepam). The performance of
traditional CYP-selective model inhibitors (for references see Turpeinen et al. 2005) was
characterized with fluorescent probe assay also as described above. Montelukast was used
for  inhibition  of  CYP2C8  activity  (Walsky  et  al.  2005)  in  all  assay  types.   All  data  points
represent the average of duplicate incubations. The enzyme activities in the presence of
inhibitors were compared with the control incubations (incubations with the solvent but
without an inhibitor).
5.3 Results
5.3.1 Sotalol and propranolol
With sotalol, no inhibition was observed in any model activity in any of the three assays
even at the highest concentration used (100 μM). With propranolol, a strong inhibition of
CYP2D6 with IC50 values  of  5.8  μM,  2.7  μM  and  2.5  μM  for  single  substrate,  fluorescent
probe and n-in-one assays were observed, respectively. Moderate inhibition of CYP1A2
with IC50 values ranging from 26 μM to 47 μM and CYP2C9 (IC50 values 40.0 μM to 88 μM)
were observed with all three assay types. In addition, inhibition of CYP2B6 activity with an
IC50 value of 41 μM was observed when the n-in-one assay was used (Table 5).
5.3.2 Citalopram and fluoxetine
Citalopram was found to inhibit CYP2D6 with IC50 values of 12 μM, 3.3 μM and 4.6 μM in
single substrate, fluorescent probe and n-in-one assays, respectively (Table 6). The CYP3A4
associated model reactions testosterone 6-hydroxylation and omeprazole 3-hydroxylation
showed inhibition with IC50 values of 32 μM and 10 μM, respectively, for citalopram when
the n-in-one test was used. Fluoxetine inhibited CYP2D6 equally well in all three assays,
with IC50 values of 0.3 μM, 0.3 μM and 0.2 μM in single substrate, fluorescent probe and n-
in-one assay, respectively. Fluoxetine was a relatively potent inhibitor towards CYP2C19
and CYP2C9, with IC50 values of 0.33 μM and 3.6 μM in the fluorescent assay, respectively.
The IC50 values were considerably higher in single substrate and n-in-one assays, with IC50
values of 33 μM and 22 μM (CYP2C19) and 49 and 12 μM (CYP2C9), respectively.
Fluoxetine inhibited CYP3A4 moderately, but the IC50 value was dependent on the assay
type and the model reaction used. The values obtained with the single substrate assay
ranged from 9.9 μM (testosterone 6	-hydroxylation) to 79 μM (midazolam 1´-
hydroxylation) and with the n-in-one assay from 7.4 μM (testosterone 6	-hydroxylation) to
65 μM (midazolam 1´-hydroxylation). The fluorescence probe assay gave a value of 17 μM.
CYP2B6 was inhibited by fluoxetine in all three assays (IC50 values between 22 μM and 85
μM). CYP2C8 was inhibited only in the fluorescence probe assay, with an IC50 value of 16
μM.
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Table 5. IC50 values (μM) of sotalol and propranolol as measured by traditional single substrate
assay, fluorescent probe assay and n-in-one approach
Sotalol Propranolol
CYP Single Fluorescent n-in-one Single Fluorescent n-in-one
1A2 > 100 > 100 > 100 31 47 26
2A6 > 100 > 100 > 100 > 100 > 100 > 100
2B6 > 100 > 100 > 100 > 100 > 100 41.1
2C8 > 100 > 100 > 100 > 100 > 100 > 100
2C9 > 100 > 100 > 100 > 100 > 100 > 100
2C19 > 100 > 100 > 100 88 40 61
2D6 > 100 > 100 > 100 5.8 2.65 2.5
2E1 > 100 > 100 > 100 > 100 > 100 > 100
3A4 > 100 > 100
-OH-MDZ > 100 > 100 > 100 > 100
   6-TES > 100 > 100 > 100 > 100
   SO-OME > 100 > 100 > 100 > 100
   3-OH-OME n.d. > 100 n.d. > 100
n.d. = not determined
Table 6. IC50 values  (μM)  of  citalopram  and  fluoxetine  as  measured  by  traditional  single
substrate assay, fluorescent probe assay and n-in-one approach
Citalopram Fluoxetine
CYP Single Fluorescent n-in-one Single Fluorescent n-in-one
1A2 > 100 > 100 > 100 > 100 > 100 > 100
2A6 > 100 > 100 > 100 > 100 > 100 > 100
2B6 > 100 > 100 > 100 62 85 22
2C8 > 100 > 100 > 100 > 100 16 > 100
2C9 > 100 > 100 > 100 49 3.6 12
2C19 > 100 > 100 > 100 33 0.33 22
2D6 12 3.3 4.6 0.3 0.3 0.2
2E1 > 100 > 100 > 100 > 100 > 100 > 100
3A4 > 100 17
-OH-MDZ > 100 > 100 79 65
-TES > 100 32 9.9 7.4
SO-OME > 100 > 100 52 24
3-OH-OME n.d. 10.0 n.d. 20
n.d. = not determined
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5.3.3 Oxazepam and diazepam
With oxazepam, moderate inhibition of CYP1A2 (IC50 = 32) and CYP2D6 (IC50 = 92 μM) was
seen with the n-in-one assay (Table 7). Other assay types showed no inhibition.  Diazepam
was  found  to  inhibit  CYP2D6  with  IC50 values of 97 μM, 82 μM and 40 μM in single
substrate, fluorescent probe and n-in-one assays, respectively. Moderate inhibition of
CYP2C19 by diazepam was seen in all assay types with IC50 values ranging from 40 μM to
46 μM. In addition, in the n-in-one assay diazepam inhibited CYP2B6 activity with an IC50
value of 58 μM.
Table 7. IC50 values  (μM)  of  oxazepam  and  diazepam  as  measured  by  traditional  single
substrate assay, fluorescent probe assay and n-in-one approach
Oxazepam Diazepam
CYP Single Fluorescent n-in-one Single Fluorescent n-in-one
1A2 > 100 > 100 31.6 > 100 > 100 > 100
2A6 > 100 > 100 > 100 > 100 > 100 > 100
2B6 > 100 > 100 > 100 > 100 > 100 58
2C8 > 100 > 100 > 100 > 100 > 100 > 100
2C9 > 100 > 100 > 100 > 100 > 100 > 100
2C19 > 100 > 100 > 100 40 46 41
2D6 > 100 > 100 92 97 82 40
2E1 > 100 > 100 > 100 > 100 > 100 > 100
3A4 > 100 > 100
-OH-MDZ > 100 > 100 > 100 > 100
-TES > 100 > 100 > 100 > 100
SO-OME > 100 > 100 > 100 > 100
3-OH-OME n.d. > 100 n.d. > 100
n.d. = not determined
5.3.4 Effect of CYP-specific reference inhibitors in the fluorescent probe assay
To further compare the three types of tests with each other, the effects of well established
reference inhibitors were evaluated in the single substrate, fluorescent probe and n-in-one
assays. The effects of well established reference inhibitors were measured in the fluorescent
probe assay and compared with the results obtained from our previous study with the
single substrate and n-in-one assays (Turpeinen et al. 2005).The results are summarized in
Table 8. Each diagnostic inhibitor was found to inhibit the model activities in a very similar
fashion. There were, however, some notable differences. Ketoconazole was at least 8-fold
more potent in the fluorescence probe assay than in the single substrate or n-in-one assays.
In the latter two assays, there were large differences in the IC50 values between different
CYP3A4 substrates. CYP2E1 model inhibitor pyridine displayed IC50 values of 2.7 μM, 6.2
μM and 37 μM for single substrate, fluorescent probe and n-in-one assay, respectively.
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Table 8. IC50 values (μM) of CYP-specific diagnostic inhibitors in traditional single substrate
assay,  N-in-1  technique  and  fluorescent  probe  assay.  Data  for  single  and  n-in-1  assays
excluding montelukast is adapted from Turpeinen et al. 2005.
CYP Inhibitor Single n-in-one Fluorescent
1A2 Fluvoxamine 0.1 0.1 0.1
2A6 Tranylcypromine 0.4 1.0 0.3
2B6 Ticlopidine 0.3 0.1 0.4
2C8 Montelukast 0.4 0.9 0.2
2C9 Sulphaphenazole 0.4 0.2 0.3
2C19 Fluconazole 24 5.7 c, 6.4 d 8.2
2D6 Quinidine 0.1 0.03 0.004
2E1 Pyridine 2.8 6.2 37
3A4
Ketoconazole 0.07 a, 1.8 b
1.8 a, 0.07 b, 0.08 e,
0.1 f 0.01
IC50 values for
a midazolam 1´-hydroxylation, b testosterone 6-hydroxylation, c omeprazole
demethylation, d omeprazole 5-hydroxylation, e omeprazole 3-hydroxylation and f omeprazole
sulphoxidation.
5.4. Discussion
In this study, three different types of tests were developed and adapted for determining
the inhibition capacities of chemical compound towards human drug-metabolizing CYP
enzymes. Nine distinct CYP forms were included in each of the assays, including CYP2B6
and CYP2C8, two forms that have recently been identified as significant contributors to
drug metabolism. The performance of the three assays was first assessed using well
established in vitro inhibitors of CYPs. To cross-validate the assays, the inhibitory
capacities of six selected drugs in clinical use were analyzed. The results show that the
three assay types yield remarkably similar results with the majority of tested CYP forms.
Of the two -receptor antagonists studied, sotalol has negligible first-pass metabolism
and the majority of oral dose is excreted unchanged in urine (Sotaniemi et al. 1979). No
inhibition of any hepatic CYP form by sotalol has been reported previously. A clear lack of
inhibition  was  observed  also  in  this  study  in  all  the  three  assay  types.  Propranolol  is
known to be a potent CYP2D6 inhibitor (Rowland et al. 1994) with moderate inhibition
affinity also against CYP1A2 (Gillam and Reilly, 1988). In the present study, all three
assays predicted these inhibitions and their magnitude correctly. Also moderate inhibition
of CYP2C19 ranging from 40 μM to 88 μM was observed in all the assays. The n-in-one
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technique suggested a moderate inhibition of CYP2B6 by propranolol with IC50 value  of
approximately 40 μM, but this was not observed in the other two assay types.
The two serotonin selective antidepressants studied, fluoxetine and citalopram, were
selected because they have widely different CYP inhibition profiles. Fluoxetine is known to
undergo extensive hepatic biotransformation mainly to the metabolite norfluoxetine (Fuller
et al. 1991), with both having a strong inhibition capacity against CYP2D6 (Stevens and
Wrighton, 1993), and notably low IC50 values for CYP3A4 (Greenblatt et al. 1996), CYP2C9
(Shader et al. 1994) and CYP2B6 (Hesse et al. 2000). In the current study, the magnitude of
inhibition towards CYP forms by fluoxetine was consistent with previous literature results.
The assay utilizing the fluorescent probe technique predicted also an inhibition against
CYP2C8, which was not observed in the other tests. To our knowledge, there are no
literature reports about inhibition of CYP2C8 by fluoxetine. With fluoxetine, the IC50 values
concerning CYP2C9 varied from approximately 0.5 μM to 33 μM depending on the assay
used.
Citalopram is considered to be one of the compounds least prone to metabolic
interactions among serotonin selective antidepressants. After continuous treatment with
citalopram, the in vivo activity of CYP2D6 has been found to be slightly reduced (Gram et
al. 1993; Baumann and Rochat, 1995), but inhibition of other CYP forms has not been
reported. In agreement with these data, citalopram showed an inhibition of CYP2D6 which
was observed in all three tests, while no inhibition of the other CYP forms was observed.
The benzodiazepine diazepam and its metabolite oxazepam were selected because of
close structural similarity (Figure 6) but drastically different metabolic profiles. Oxazepam
belongs structurally to 3-hydroxybenzodiazepines, which undergo direct conjugation by
phase II enzymes and excretion to urine, while diazepam undergoes hepatic metabolism
(Chouinard et al. 1999). In the present study, the results with both oxazepam and diazepam
were in agreement with literature information.
Reference inhibitors were found to perform mainly as expected and the IC50 values were
within the same order of magnitude with all the three screening tests. The largest
discrepancy was observed with the  CYP2E1 inhibitor  pyridine,  which yielded IC50 values
ranging from 2.8 μM to 37 μM in the single substrate and n-in-one assays, respectively. The
reason for this remains open and is discussed previously in detail in a paper by Turpeinen
et al. (2005). Inhibition of CYP3A4 was tested with ketoconazole using multiple probe
substrates. It was not unexpected that the inhibition potency of ketoconazole varied
depending on the specific reaction measured. Previously, inhibition of CYP3A4 has been
shown to be substrate-dependent (Harlow and Halpert, 1998). A drug molecule can bind to
an allosteric site of CYP3A4 and change the affinity of the substrate-binding site (Wang et
al. 2000). Molecular modelling and metabolism studies suggest that the active site of
CYP3A4 has the capacity to accommodate large molecules and more than one substrate at
the same time (Shou et al. 1994; Lewis et al. 1996). Because of the unique properties of
CYP3A4, the reactions catalyzed do not always follow typical enzyme kinetics. Thus,
CYP3A4 enzyme kinetics is unpredictable and depends on many different factors such as
the substrates and inhibitors used (Galetin et al. 2005).
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Figure 6. Chemical structures of study compounds: a) sotalol, b) propranolol, c) citalopram,
d) fluoxetine, e) oxazepam and f) diazepam
In  this  study  this  effect  was  observed  especially  with  citalopram,  which  showed  a
moderate CYP3A4 inhibition in both the single substrate and n-in-1 assays when
testosterone 6-hydroxylation was measured, but no inhibition occurred when midazolam
1´-hydroxylation assay was carried out. The use of multiple CYP3A4 substrates is therefore
recommended when screening the CYP3A4 inhibition potential of new chemical entities.
In conclusion, two in vitro assays with higher throughput, the n-in-one technique and
the fluorescent probe assay, were found to be useful and suitable for measuring the
inhibition of major drug-metabolizing CYP activities compared to a conventional single
substrate assay. The rationale behind using more efficient and robust methods in early
stage  of  drug  development  is  the  cost-effectiveness  of  screening  methods  and  the  aim  to
rank lead candidates for selection purposes. These tests provide tentative inhibition values
and point out the CYP forms potentially inhibited. If detailed and more accurate
information is wanted, the traditional single substrate technique would still be the
recommended choice.
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6 Inhibition studies and 3D-QSAR of CYP1A2
Inhibitors 2
Abstract: The purpose of this study was to determine the CYP1A2 inhibition potencies of
structurally diverse compounds, to create a comprehensive 3D-QSAR model of CYP1A2
inhibitors,  and  to  use  this  model  to  predict  the  inhibition  potencies  of  an  external  set  of
compounds.  Fifty  two  compounds  including  naphthalene,  lactone  and  quinoline
derivatives were assayed in a 96-well plate format for CYP1A2 inhibition activity using 7-
ethoxyresorufin-O-dealkylation as the probe reaction. The IC50 values of the tested
compounds varied from 2.3 
M to over 40 000 
M. Based on this data set, a comparative
molecular field analysis (CoMFA) and GRID/GOLPE models were created which yielded
novel structural information about the interaction between inhibitory molecules and the
CYP1A2 active site. The created CoMFA model was able to accurately predict inhibitory
potencies of several structurally unrelated compounds, including selective inhibitors of
other cytochrome P450 forms.
2 Adapted with permission of American Chemical Society from: Korhonen LE, Rahnasto M, Mähönen NJ, Wittekindt C,
Poso A, Juvonen RO and Raunio H. Predictive three-dimensional quantitative structure-activity relationship of
cytochrome P450 1A2 inhibitors. J Med Chem. 48: 3808–15, 2005
38
6.1 Introduction
Several computational approaches, especially QSARs, have been used to characterize the
molecular properties of substrates and inhibitors of the CYP1A2 enzyme. The overall result
of these studies is that substrates of CYP1A2 are moderately basic and planar molecules
with medium volume and low total interaction energies (	E value), but there is no clear
correlation between compound lipophilicity and inhibitory effect. (Fuhr et al. 1993; Sanz et
al. 1994; Lee et al. 1998; De Rienzo et al 2000; Lozano et al. 2000; Lewis, 2000; Moon et al.
2000)
The aims of this study were to determine the CYP1A2 inhibition potencies of
structurally diverse compounds, to create a comprehensive 3D-QSAR model of CYP1A2
inhibitors, and to use this model to predict the inhibition potencies of an external set of
compounds. To achieve this goal, the abilities of 52 compounds including naphthalene,
lactone and quinoline derivatives to inhibit CYP1A2 catalyzed 7-ethoxyresorufin-O-
dealkylation reaction were examined. Based on this data set, a comparative molecular field
analysis (CoMFA) and a GRID/GOLPE analysis were carried out.
6.2 Materials and methods
The materials and general methods used are described in Chapter 4.
6.2.1 Determination of inhibition potency
The 7-ethoxyresorufin O-dealkylation assay is based on the detection of fluorescence
emitted by resorufin (Burke et al. 1985). The assay was adapted to the 96-well plate format
(Chapter 4). All inhibitors were dissolved in ethanol, and the final concentration of ethanol
was  2%  in  all  incubations.  Each  inhibitor  was  pre-screened  using  pooled  human  liver
microsomes at inhibitor concentrations ranging from 0.1 
M to 40 000 
M. The actual IC50
values  were  determined  using  expressed  human  CYP1A2  enzyme  and  seven  inhibitor
concentrations.
6.2.2 GRID/GOLPE model
In addition to the standard CoMFA model (Chapter 4), another model was created using
the GRID/GOLPE method. GRID fields were created using a phenolic hydroxyl probe with
1  Å  grid  spacing  and  the  positive  cut-off  was  set  to  5  kcal/mol.  The  phenolic  hydroxyl
probe was chosen because it represents a hydrogen bond donor or acceptor which was
found  to  be  suitable  for  examining  aromatic  systems.  GRID  fields  of  the  molecules  were
analyzed with GOLPE (Wade et al. 1993; Baroni et al. 1993).
Initially the GRID/GOLPE analysis included several variables that did not describe
interactions between inhibitory molecules and the GOLPE hydroxyl probes. Therefore the
SRD and the F.Factorial Selection procedures were used to reduce the number of variables
in  the  final  GOLPE  model.  Data  pre-treatment  was  done  using  the  zeroing  option
correction. To diminish the amount of noise in the data, positive values smaller than 0.10
and negative values greater than -0.01 were zeroed. The SRD analysis was performed to
select important variables for the interaction using a maximum dimensionality of 5 with a
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critical  distance  cut-off  value  of  1  Å  and  collapsing  distance  cut-off  value  of  2  Å.  The
F.Factorial Selection procedure was used with a maximum dimensionality of 2 and the
Random Groups Method with 5 groups to separate a variable that significantly improves
predictability. The final model was validated by using PLS crossvalidation with 5 random
groups.
6.3 Results
6.3.1 Inhibition of CYP1A2 activity
CYP1A2 substrates and inhibitors are usually planar small volume molecules that are
neutral or weakly basic. Fifty two naphthalene and lactone derivatives as well as other
compounds partially fitting these criteria were tested for inhibitory potency toward
CYP1A2 enzyme. The structures of the compounds are shown in Figures 7 and 8.
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Figure 7. Structures of naphthalene type compounds used in inhibition assays
Naphthalene
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CH3
1-Methylnaphthol                1-Chloronaphthalene                      1-Naphthol                  2-Methylnaphthalene
2-Ethylnaphthalene              2-Fluoronaphthalene                      2-Naphthol 2-Methoxynaphthalene
1,2-Dimethylnaphthalene       1,3-Dimethylnaphthalene        1,4-Dimethylnaphthalene      1,4-Dichloronaphthalene
1,5-Dichloronaphthalene     1,5-Dimethylnaphthalene         1,6-Dimethylnaphthalene      1,7-Dimethylnaphthalene
2,6-Dimethylnaphthalene        2,7-Dimethylnaphthalene                    Quinaldine 3-Methylquinoline
2,4-Dimethylquinoline          2,6-Dimethylquinoline              2,7-Dimethylquinoline          3-Methylisoquinoline
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Figure 8. Structures of lactones and other compounds used in inhibition assays
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The IC50 values of these compounds were measured using 7-ethoxyresorufin O-
dealkylation as the probe reaction. Recombinant human CYP1A2 was used as the enzyme
source to exclude any interference from other cytochrome P450 forms present in human
liver microsomes. The enzymatic activity was assayed in constant conditions using seven
different concentrations of each inhibitor. Figure 9 represents an example of concentration
dependent inhibition of the enzyme activity by two structurally different compounds (2,6-
dimethylquinoline and 2-methylnaphthalene).
Figure 9. Inhibition of  CYP1A2 activity by two selected compounds.  2,6-dimethylquinoline ()
and 2-methylnaphthalene () were used as inhibitors.
The  lowest  IC50 values were obtained with 1,4-dichloronaphthalene and 2,4-
dimethylquinoline (<3 
M) and the highest values with 
-caprolactone and 4-
methoxyfuran2(5H)-one (>40 mM) (Tables 9 and 10). Most of the naphthalene derivatives
were more potent inhibitors than the lactones and other compounds tested.
The IC50 values of all naphthalene derivatives were lower than the IC50 value  of
naphthalene as methyl, chloro, ethyl, fluoro and hydroxyl substitutions decreased the IC50
value. In general, disubstituted naphthalenes or quinolines were more potent than
monosubstituted or unsubstituted ones. Especially electronegative substitutions at position
1 of naphthalene increased the inhibitory potency. The IC50 values of quinoline derivatives
were lower than the corresponding naphthalene derivatives, indicating that a heterocyclic
nitrogen atom decreases the IC50 value (Table 9).
The inhibitory potencies of 11 lactones were tested (Table 10). The simple lactone ring
structures were weak inhibitors, -caprolactone being the least potent. With alkyl
substituted - and -lactones, the inhibition potency increased with increasing side chain
length. The optimum length of the side chain was 7 carbons. The IC50 value decreased more
than  300-fold  when  the  side  chain  length  increased  from  methyl  to  hexyl  in  five  ring
lactones. The most potent lactone inhibitor was undecanoic--lactone (IC50 = 45 
M).
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Table 9. Inhibition potencies of naphthalene type compounds for CYP1A2
Compound IC50 value (
M)
95% confidence
intervals
pIC50 value
1,4-Dichloronaphthalene 2.3 0.9–3.7 5.64
2,4-Dimethylquinoline 2.4 1.5–3.2 5.62
1-Naphthol 3.2 2.4–4.0 5.49
2,6-Dimethylquinoline 3.3 2.7–3.9 5.48
1,4-Dimethylnaphthalene 3.6 2.8–4.2 5.44
2,7-Dimethylquinoline 4.4 3.5–5.3 5.36
1,2-Dimethylnaphthalene 5.5 3.4–7.6 5.26
1,7-Dimethylnaphthalene 7.5 4.5–11 5.12
1,3-Dimethylnaphthalene 7.9 5.9–9.8 5.10
2-Methoxynaphthalene 13 11–15 4.89
3-Methylquinoline 13 9.7–17 4.89
1,5-Dichloronaphthalenea 14 8.0–19 4.85
2-Naphthol 17 15–18 4.77
2-Ethylnaphthalene 19 12–26 4.72
3-Methylisoquinoline 21 18–24 4.68
1,6-Dimethylnaphthalene 25 17–33 4.60
Quinaldine 40 34–45 4.40
1,5-Dimethylnaphthalenea 42 29–56 4.38
2-Fluoronaphthalene 49 34–64 4.31
1-Chloronaphthalene 50 44–56 4.30
2,6-Dimethylnaphthalene 52 33–72 4.28
2,7-Dimethylnaphthalene 65 36–91 4.19
1-Methylnaphthalene 110 81–150 3.96
2-Methylnaphthalene 120 106–130 3.92
Naphthalene about 700 3.15
a Used only in the external set of test compounds
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Table 10. Inhibition potencies of lactones and other compounds for CYP1A2
Compound IC50 value (
M)
95% confidence
intervals
pIC50 value
2-(p-Tolyl)ethylaminea 14 12–17  4.85
Undecanoic--lactone 45 34–56 4.35
4-Chlorobiphenyla 49 29–69 4.30
Butylcyclohexane 55 45–66 4.26
-Dodecanolactone 58 49–68 4.24
(+/-)-Undecaonic--lactone 72 53–90 4.14
2-Indanone 80 51–110 4.10
-Decanolactone 110 75–150 3.96
Biphenyl 160 74–240 3.80
-Decanolactone 230 190–270 3.64
2-Chlorobiphenyla 230 150–310 3.64
2-Coumarone 260 170–340 3.59
4-Methoxybenzaldehydea 270 180–350 3.57
-Nonanoic-lactone 310 230–390 3.51
2-Benzoxazolinone 370 230–510 3.43
Indan 550 430–660 3.26
2,3-Dihydrobenzofuran 1200 880–1500 2.92
-Phenyl--butyrolactone 2300 1600–3000 2.64
Butylbenzyl 3700 2400–4900 2.43
Nicotine 4100 2600–5600 2.39
4,6-Dimethyl--pyron 4500 3300–5600 2.35
-Heptalactone 4500 3300–5700 2.35
Cotinine 5400 2400–8400 2.27
-Caprolactone 9900 5600–14000 2.00
-Valerolactone 15000 11000–20000 1.82
-Caprolactone > 40000 >1.40
4-Methoxyfuran2(5H)-one > 40000 >1.40
a Used only in the external set of test compounds
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In addition to lactone and naphthalene derivatives, selected other compounds were
tested for CYP1A2 inhibition (Table 10). When the cyclohexane ring of butylcyclohexane
was replaced by phenyl, the IC50 value increased about 60-fold. 2-Coumarone and 2-
indanone, which have a carbonyl group, were more potent inhibitors than indan and 2,3-
dihydrobenzofuran. A halogen group at position 4 of the biphenyl increased and at
position 2 decreased inhibitory potency.
6.3.2 CoMFA and GRID/GOLPE analysis
Forty six compounds listed in Tables 9 and 10 were analyzed using CoMFA and
GRID/GOLPE methods. Also listed in Table 9 and Table 10 are six compounds used in the
external test set. After data pre-treatment, GRID/GOLPE analysis gave an r2 value of 0.86,
followed by a q2 value of 0.73 with 3 components and SDEP of 0.60. In the final model, the
smart region definition (SRD) method with F.Factorial Selection was used to remove
variables that did not correlate with the inhibition potency. The obtained statistics of the
models are summarized in Table 11, and the plots for the training set of both models are
shown in Figure 10.
Table 11. Statistics from the CoMFA and GRID/GOLPE analyses
Models q2 r2 SPRESS/SDEP N
CoMFA 0.69 0.87 0.67 3
GRID/GOLPE 0.79 0.90 0.52 3
q2 = the crossvalidated correlation coefficient with 5 random groups; r2 = correlation coefficient; SPRESS
(Sybyl), SDEP (GOLPE) = standard deviations for the error of predictions; N = number of PLS (partial
least squares) components.
Figure 10. Plots for  the training set  (actual/predicted IC50 values)  of  the  CoMFA model  (r2 =
0.87, left panel) and the GOLPE/GRID model (r2 = 0.90, right panel)
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The CYP1A2 CoMFA model is represented as 3D contour maps with 2,7-
dimethylquinoline as the reference structure (Figure 11). The contours of the steric map are
shown in green and yellow regions, in which bulky groups enhance or decrease inhibition
potency, respectively. Those of the electrostatic map are shown in red and blue areas in
which a more negative charge enhance or decrease inhibition potency, respectively.
Negative charge favoured areas which were near to a nitrogen atom and position 6 and 8
of the quinoline ring indicate that a partial negative charge here tended to increase the
inhibition potency. The broad negative charge disfavoured area shown in blue was
displayed near position 3 of the ring. The sterically favoured green area was located
around substitution at position 7 of quinoline in the CoMFA model.
A stereo figure of the GOLPE coefficient map (Figure 12) displays large continuous
regions, where the interaction with the hydroxyl probe is favourable (cyan) or
unfavourable (purple). The favourable region is around the nitrogen atom and partly
above and under the aromatic ring structure. These regions of the inhibitor can act as
hydrogen  bond  acceptors  or  donors.  The  electronic  configuration  of  the  OH  probe  is
defined  so  that  it  interacts  with  the –electron of the conjugated system like planar
aromatic ring or double bond. It makes strong hydrogen-bonding interactions which may
account for the shape of the interaction regions with the molecular structures (Pastor et al.
1997). The unfavourable regions reside in the plane of the ring and are spread all around
the ring except to the region nearby the nitrogen atom.
The prediction power of the CoMFA model was evaluated by estimating pIC50 values for
an external test set of compounds, including the six compounds tested in this study (Table
9 and Table 10). These six compounds were chosen on the basis that they resemble in
structure the ones in the training set but also contain features that differ from the training
set compounds. The values for five additional compounds that are well-known substrates
and inhibitors of CYP enzymes were obtained from Turpeinen et al. 2005 (Figure 13). As
summarized in Table 12, the predictions of pIC50 values for the external set of molecules
differed by less than 0.1 log units from the actual values for biphenyls, 1,5-
dichloronaphthalene and 4-methoxybenzaldehyde. The predictions of pIC50 values for the
other molecules were within 0.13–0.67 log units of the actual values.
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Figure 11. Stereo  figure  of  colour  contour  maps  of  CYP1A2 CoMFA.  Red  and  green  represent
areas where more negative partial charge and bulkier groups increase inhibition potency,
respectively. Blue and yellow represent areas where more negative partial charge and bulkier
groups decrease inhibition potency, respectively. The reference structure is 2,7-
dimethylquinoline.
Figure 12. Stereo figure of GOLPE coefficient map with 2,7-dimethylquinoline as the reference
structure. The cyan regions describe favourable interactions and the purple regions
unfavourable interactions between the hydroxyl probe and the molecules.
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Figure 13. Structures of the external set of test compounds
Table 12. Validation of CYP1A2 model
pIC50
Inhibitor Experimental Predicted Residual
2-(p-Tolyl)ethylamine 4.85 4.53 0.32
4-Chlorobiphenyl 4.30 4.30 0
2-Chlorobiphenyl 3.64 3.59 0.05
4-Methoxybenzaldehyde 3.57 3.51 0.06
1,5-Dichloronaphthalene 4.85 4.80 0.05
1,5-Dimethylnaphthalene 4.38 4.80 0.42
Ketoconazolea 4.12 4.30 0.18
Quercetina 5.18 5.05 0.13
Quinidinea 4.59 3.92 0.67
Sulfaphenazolea >4 4.05 -
Tranylcyprominea 4.01 4.30 0.29
a Experimental data from Turpeinen et al. 2005
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6.4 Discussion
The main purpose of this study was to create a QSAR model to understand in greater
detail the structural properties of inhibitors of the human CYP1A2 enzyme. The inhibition
potency of a series of 52 chemicals was determined against the CYP1A2 enzyme. With this
data set, CoMFA and GRID/GOLPE models were created which yielded novel structural
information about the interaction between inhibitory molecules and the CYP1A2 active
site. In addition, the developed CYP1A2 CoMFA model accurately predicted the inhibition
potencies of several structurally unrelated compounds.
Some  disubstituted  naphthalene  and  quinoline  derivatives  were  found  to  be  potent
inhibitors of CYP1A2. Quinoline derivatives had lower IC50 values than the corresponding
naphthalene derivatives, indicating that a heterocyclic nitrogen atom increases inhibition
potency. Also hydrophobic substituents at position 1 of the naphthalene ring increase
inhibition potency. Hydroxyl, halogen and methyl substitutions of the naphthalene ring
decreased the IC50 values. The IC50 values of molecules decreased as the molecular volume
of lactones and the length of alkyl side chain increased.
Previously published QSAR studies on the CYP1A2 enzyme were based on a limited
number of structurally diverse compounds and have not been used to predict the
inhibition potency of new compounds. One of the first human CYP1A2 3D-QSAR studies
was carried out on quinolone antibacterials (Fuhr et al. 1993). Four pharmacophore
features were suggested to be involved in binding of quinolone-type CYP1A2 inhibitors in
the active site. No correlation between lipophilicity and inhibitory effect could be observed
in this study (Fuhr et al. 1993). Based on the experimental finding that a methyl group at
position 8 of the xanthine ring is important for CYP1A2 inhibition, a subsequent theoretical
model was created using a molecular electrostatic potential approach (Sanz et al. 1994).  A
QSAR analysis using inhibition data of 16 naturally occurring flavonoids showed that
planar molecules with a small volume to surface area were the most potent inhibitors, the
number  of  hydroxyl  groups  being  inversely  proportional  to  inhibition  potency,  and
glycosylation of the free hydroxyls could reduce the inhibition potency (Lee et al. 1998)
Two different studies docked selected substrates into the active site of homology models
of the CYP1A2 protein and analyzed the binding mode of the ligand-enzyme complex in
terms of molecular mechanics calculations (De Rienzo et al. 2000; Lozano et al. 2000).
Lozano et al. used the COMBINE method for energy partition and adjacent 3D-QSAR
analysis. Subsequently they performed a GRID/GOLPE analysis using the phenylic OH-
group. The combination of both methods provided useful insights into the positions of
likely hydrogen bonding or placement of hydrophobic or bulky groups. A previous study
suggested that CYP1A2 substrates are generally neutral or protonated molecules (Lewis,
2000).
The correlation between electrostatic interactions and pIC50 values  appeared  in  the
CoMFA maps as negative charge favored areas which are near the nitrogen atom of the
quinoline ring. Also electronegative substituents at position 1 of naphthalene ring are
important for inhibition. This explains the finding that 1,4-dichloronaphthalene and 1-
naphthol  are  quite  potent  inhibitors  compared  with  the  naphthalenes  with  halogen  or
other electronegative substituent at position 2. In addition, there is an attractive interaction
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between the hydroxyl probe and an inhibitor favourable area located around position 1 of
the quinoline ring near to the nitrogen atom. The hydroxyl probe is capable of donating
and accepting one hydrogen bond with a hydrogen acceptor or donor atom or with the –
system of the aromatic ring. GRID/GOLPE maps can describe interactions between
nitrogen and hydroxyl group or dipole-induced dipole interaction between aromatic ring
and the probe (Pastor et al. 1997). The nitrogen atom can act as hydrogen bonding acceptor
atom which indicates that hydrogen bonding is an important interaction between
quinoline type inhibitors and the CYP1A2 enzyme.
Most of the CYP1A2 substrates are hydrophobic with a high log P value, suggesting that
hydrophobic interactions play an important role in binding to CYP1A2. The created
CoMFA model confirms this, because the CoMFA model shows that alkyl substitutions at
position 7 increase the inhibitory potency. The alkyl side chain of lactones can interact with
hydrophobic amino acids in the CYP1A2 protein. A large steric favoured region is located
near the 7-position in the CoMFA map. Also substitution of naphthalene with hydrophobic
substituents  like  halogen  or  methyl  groups  increases  the  inhibition  potency.  This  data
suggests that the binding pocket of the CYP1A2 enzyme is composed of mostly
hydrophobic  and  aromatic  amino  acids  with  polar  amino  acids  for  hydrogen  bonding
being present near to the heme centre (Dai et al. 2000). In addition to using steric and
electrostatic fields, a CoMFA model was created using log P values as an additional
variable. This did not improve in the model.
The created CoMFA model predicted very well the inhibitory potencies of the test set of
compounds. The best predictions were obtained for biphenyls and 1,5-dichloronaphthalene
with predicted pIC50 values being within 0.05 log units of the actual values. The model also
predicted well the CYP1A2 pIC50 values of several well known inhibitors of other
cytochrome P450 forms - ketoconazole (CYP3A4), tranylcypromine (CYP2A6), quinidine
(CYP2D6), quercetin (CYP2C8), and sulfaphenazole (CYP2C9) (Pelkonen et al. 1998;
Taavitsainen et al. 2001). This is remarkable because the structures of these compounds
differ considerably from the ones used in the training set.
The current CoMFA model takes into account both steric and electrostatic interactions.
The CoMFA approach described in this report represents a robust method to screen for
inhibitory properties of compounds toward CYP1A2. A similar approach will be applicable
to other xenobiotic metabolizing cytochrome P450 as well. We have shown earlier that
CoMFA modelling can predict reasonably well the actual inhibition characteristics of
lactones and naphthalenes toward the human CYP2A6 and mouse CYP2A5 enzymes, and
that naphthalene is metabolized by these CYP forms (Juvonen et al. 2000; Asikainen et al.
2003). A CoMFA method similar to the one described here has been used for modelling the
CYP2A6 enzyme (Rahnasto et al. 2005). In the present CYP1A2 QSAR study, the
GRID/GOLPE analysis was also applied which improved the precision of the model
through exclusion of variables that were not significant.
The model presented here is clearly superior to previously published QSAR models of
CYP1A2. The current training set is large and contains structurally diverse compounds. All
biological data used in the training set is generated with internally fully consistent
methods.  The model  is  reasonably predictive  even for  compounds that  differ  in  structure
from the ones in the training set. Using the hydroxyl probe yielded information about the
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importance of dipole-induced dipole interaction in the active site of CYP1A2. The
GRID/GOLPE analysis gave insight into the shape of the interaction regions. The presented
CoMFA  and  GRID/GOLPE  models  are  in  agreement  with  previous  studies  concerning
areas of H-bonds and electrostatic field (Fuhr et al. 1993; Sanz et al. 1994; Lee et al. 1998; De
Rienzo et al 2000; Lozano et al. 2000). However, due to the statistical analysis of a large
training  set  with  structurally  diverse  compounds  the  present  model  is  more  general  and
predictive  than  the  previous  ones.  Especially  the  spatial  orientation  in  the  regions  where
H-bonds  are  likely  to  occur  and  the  regions  where  bulky  groups  enhance  the  inhibitory
potential could be determined both in a qualitative and quantitative way.
There are two major reasons for studying inhibitory potencies of drug candidates and
other xenobiotics: First, potent inhibition by a drug candidate gives an early warning about
potential  DDIs  during its  clinical  use.  Second,  evidence of  inhibition capabilities  suggests
that the compound may be a substrate for the cytochrome P450 studied. This applies
especially to competitive inhibitors. Because competitive inhibitors are usually also
substrates of cytochrome P450, screening of inhibitory properties serves as a good starting
point for substrate specificity studies for any chemical compound. Inhibitor orientation in
the  CoMFA  model  provides  clues  on  how  it  is  coordinated  toward  the  cytochrome  P450
heme iron if the oxidation pattern of at least one molecule in the training set is known.
Thus, a CoMFA model based on inhibition data can represent a starting point to the much
more complex task of predicting the metabolism of novel compounds.
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7 Inhibition studies and 3D-QSAR of CYP2B6
Inhibitors 3
Abstract: The cytochrome P450 2B6 (CYP2B6) enzyme metabolises a number of clinically
important drugs. Drug-drug interactions resulting from inhibition or induction of CYP2B6
activity may cause serious adverse effects. The aims of this study were to construct a three-
dimensional structure-activity relationship (3D-QSAR) model of the CYP2B6 protein and
to identify novel potent and selective inhibitors of CYP2B6 for in vitro research purposes.
The inhibition potencies (IC50 values) of structurally diverse chemicals were determined
with recombinant human CYP2B6 enzyme. Two successive models were constructed using
Comparative Molecular Field Analysis (CoMFA). Three compounds proved to be very
potent and selective competitive inhibitors of CYP2B6 in vitro (IC50<1 μM): 4-(4-
chlorobenzyl)pyridine (CBP), 4-(4-nitrobenzyl)pyridine (NBP), and 4-benzylpyridine (BP).
A complete inhibition of CYP2B6 activity was achieved at a 0.1 μM concentration of 4-(4-
chlorobenzyl)pyridine, whereas other CYP related activities were not affected. Forty-one
compounds were selected for further testing and construction of the final CoMFA model.
The created CoMFA model was of high quality and predicted accurately the inhibition
potency  of  a  test  set  (n=7)  of  structurally  diverse  compounds.  Two  CoMFA  models  were
created which revealed the key molecular characteristics of inhibitors of the CYP2B6
enzyme. The final model accurately predicted the inhibitory potencies of several
structurally unrelated compounds. CBP, BP and NBP were identified as novel potent and
selective  inhibitors  of  CYP2B6.  Especially  CBP is  a  suitable  inhibitor  for in vitro screening
studies.
3 Adapted with permission of John Wiley and Sons from: Korhonen LE, Turpeinen M, Rahnasto M, Wittekindt C, Poso
A, Pelkonen O, Raunio H and Juvonen RO. New potent and selective cytochrome P450 2B6 (CYP2B6) inhibitors based
on three-dimensional quantitative structure-activity relationship (3D-QSAR) analysis. Br J Pharmacol. 150: 932–42,
2007
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7.1 Introduction
Several inhibitors of CYP2B6 have been described including ticlopidine, clopidogrel,
thioTEPA, memantine, and 2-phenyl-2-(1-piperidinyl)propane, but they do not adequately
distinguish between different CYP forms (Turpeinen et al. 2006). Thus, more selective
CYP2B6 inhibitors are needed for in vitro drug development and drug interaction studies.
The aims of this study were (1) to determine the CYP2B6 inhibition potencies of
structurally diverse compounds to create a database for structure-activity relationship
analysis  (2)  to  construct  a  comprehensive  3D-QSAR  (CoMFA)  model,  and  (3)  to  identify
novel, potent and selective inhibitors of CYP2B6.
In this study we describe a 3D-QSAR model for CYP2B6 inhibitors using the IC50 values
generated with cDNA-expressed CYP2B6. A total of forty-one chemicals were screened.
Some of the chemicals were selected from our extensive database and further expanded
with structures  related to  CYP2B6 substrates  and inhibitors.  Three  potent  inhibitors  were
found and two of these compounds were also highly CYP2B6 selective. The CoMFA model
created was also used to accurately predict the IC50 values of a test set of seven compounds
not present in the training set.
7.2 Materials and methods
The materials and general methods used are described in Chapter 4.
7.2.1 Determination of inhibition potency
The 7-ethoxy-4-trifluoromethylcoumarin O-deethylation activity assay is based on the
detection of fluorescence emitted by the metabolite 7-hydroxy-4-trifluoromethylcoumarin.
The incubations were performed in 96-well plates (Chapter 4). 7-ethoxy-4-
trifluoromethylcoumarin varied between 1 and 17 μM in the determination of inhibition
type and the inhibition constant Kic. All inhibitors were dissolved in DMSO, and to ensure
complete solubility of the compounds, a final concentration of 2% DMSO was used in the
incubations. This concentration of DMSO caused a 17% inhibition in CYP2B6 catalytic
activity,  and  this  effect  was  taken  into  account  in  the  experiments.   Each  inhibitor  was
prescreened using inhibitor concentrations ranging from 0.001 to 1000 μM. The actual IC50
values were determined using a narrower range of seven concentrations. All IC50 values
were determined in two separate experiments. The apparent Km and  Vmax of 7-ethoxy-4-
trifluoromethylcoumarin was also determined. The IC50, the apparent Km and the apparent
Vmax values were calculated using non-linear regression analysis with Prism 4.0TM
software (San Diego, CA, USA).
7.2.2 Enzyme assays using human liver microsomes
To  assess  CYP  selectivity  of  novel  inhibitors,  a  CYP  screen  was  carried  out  using  CYP
specific substrates and human liver microsomes as the enzyme source. The incubation
conditions, analysis and instrumentation used to assess the enzyme activities of CYP1A1/2
(ethoxyresorufin O-deethylation), CYP2A6 (coumarin 7-hydroxylation), CYP2C9
(tolbutamide hydroxylation), CYP2D6 (dextromethorphan O-demethylation), CYP2E1
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(chlorzoxazone 6-hydroxylation), CYP3A4/5 (midazolam 1´-hydroxylation) and multiple
CYPs (7-ethoxycoumarin O-deethylation) have been described previously in detail in
Taavitsainen et al. (2001). The bupropion hydroxylation assay and the analytical methods
for CYP2B6 were previously described by Turpeinen et al. (2004). The amodiaquine N-
desethylation assay for CYP2C8 was a modification from Li et al. (2002): incubation
mixtures contained 0.5 mg protein/ml and 30 μM amodiaquine and the incubation time
was 20 min. Omeprazole 5-hydroxylation and sulfoxidation assays for CYP2C19 and
CYP3A4, respectively, were adapted from Äbelö et al. (2000): incubation mixtures
contained 0.5 mg microsomal protein/ml and 40 μM omeprazole and the incubation period
was 20 min. Otherwise the incubations contained buffer and NADPH and were performed
as described above.
Each reaction mixture was preincubated for 2 minutes at +37 C in a shaking incubator
block (Eppendorf Thermomixer 5436, Hamburg, Germany). The reaction was started by
adding NADPH and terminated by adding 200 μl of ice-cold acetonitrile and subsequently
cooled in an ice bath to precipitate the proteins. The mixture was vortex mixed and spun at
10,000g for 15 minutes. Supernatants were collected and stored at -20 C until analyzed. In
experiments directed at revealing mechanism-based inhibition, the inhibitors were pre-
incubated  with  NADPH  for  15  min  before  the  reaction  was  started  by  the  addition  of
substrate.
7.3 Results
7.3.1 Inhibition of CYP2B6 activity in vitro and initial CoMFA model
First, 25 compounds were analyzed for CYP2B6 inhibition potency (IC50 values) (Table 13).
The IC50 values of these compounds were measured using recombinant CYP2B6 catalyzed
7-ethoxy-4-trifluoromethylcoumarin O-deethylation as the probe reaction. The Km value of
7-ethoxy-4-trifluoromethylcoumarin was 4.0 μM (1.6-6.4 μM 95% confidence interval) and
the  Vmax value 2.4 nmol/(min x nmol CYP) [1.8 - 3.0 nmol/(min x nmol CYP)]. The
enzymatic activity was assayed under constant conditions using seven different
concentrations of each inhibitor. These compounds were selected from our own structural
database.  This  database  consists  of  compounds  used  in  our  previous  studies  on  CYP2A6
and CYP1A2 (Rahnasto et al. 2005; Chapter 6).  Based on this series of compounds, an
initial CoMFA model was created to find out the key structural features which increase
inhibition  potency.  This  CoMFA  model  revealed  the  location  of  a  hydrophobic  bulky
group and an acceptor atom that affect inhibition potency. Based on this information and
the 2D structure of a known potent CYP2B6 inhibitor, ticlopidine, 16 new pyridine and
phenyl derivatives were selected and tested.
The  lowest  IC50 values  were  obtained  with  pyridine  and  diphenylmethane  derivatives
(Table 13). The heterocyclic nitrogen of benzylpyridine and benzoylpyridine increased the
inhibitory potency. Benzylpyridines were found to be more potent than benzoylpyridines,
as the sp2 oxygen decreased inhibitory potency. Of the polyaromatic compounds, 1-
naphthol was the most potent inhibitor (IC50 = 9.1 μM). In contrast, 2-naphthol was a more
than 7-fold weaker inhibitor.
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Table 13. Inhibition potencies of compounds towards CYP2B6
Compound
IC50
(μM)
95 %
Confidence
intervals
pIC50
(M)
4-(4-Chlorobenzyl)pyridine (CBP) 0.3 0.2-0.4 6.52
4-Benzylpyridine (BP) 0.4 0.3-0.6 6.40
4-(4-Nitrobenzyl)pyridine (NBP) 0.4 0.4-0.5 6.40
4-(4-Chlorobenzoyl)pyridine 1.5 1.2-1.8 5.82
2-Benzylaniline 4.4 2.7-6.2 5.36
4-Hydroxydiphenylmethane 5.0 2.5-7.5 5.30
4-Benzoylpyridine 5.2 3.8-6.5 5.28
4,4-DDM 6.8 3.9-9.8 5.17
1-Naphthola 9.1 6.6-12 5.04
4-Chlorobenzophenone 13 8.3-17 4.89
-Dodecanolactonea 22 14-31 4.66
Undecanoic--lactonea 35 27-44 4.46
4-Methoxybenzaldehydea 37 27-47 4.43
(Table continues)
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Table 13 (continued)
2-Methoxynaphthalenea 37 29-45 4.43
Bromodiphenylmethane 39 29-49 4.41
2-(p-Tolyl)ethylaminea 45 29-60 4.35
4-Bromo-benzaldehyde 50 34-65 4.30
2-Naphthola 67 41-96 4.17
4-Hydroxybenzophenone 95 49-140 4.02
4-Bromobenzylbromide 96 67-130 4.02
2,4-Dimethylquinolinea 140 94-180 3.85
-Tetralonea 150 118-170 3.82
-Decanolactonea 150 130-180 3.82
Quinaldinea 310 210-410 3.51
2-Indanonea 350 240-450 3.46
4-Hydroxybenzaldehyde 370 300-430 3.43
3-Methylisoquinolinea 390 240-540 3.41
(Table continues)
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Table 13 (continued)
3-Methylquinolinea 420 250-580 3.38
2,7-Dimethylquinolinea 420 320-510 3.38
3,4-Dihydroxybenzaldehydea 440 290-580 3.36
2,6-Dimethylquinolinea 480 350-620 3.32
2-(4-Aminophenyl)-ethanola 630 220-1000 3.20
2,3-Dihydrobenzofurana 670 330-1000 3.17
Butylbenzenea 820 610-1000 3.09
-Phenyl--butyrolactonea 1100 750-1500 2.96
2-Coumaronea 1100 610-1700 2.96
2-Benzoxalinonea 1600 880-2400 2.80
-Heptalactonea 2400 1600-3100 2.62
-Hexalactonea 4700 3800-5700 2.33
-Caprolactonea 6400 4900-8000 2.19
-Caprolactonea 28 000 26 000-30
000
1.55
a Compounds used in the initial CoMFA model
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The other polyaromatic compounds were even weaker, 2-benzoxalinone having the
highest IC50 value (1600 μM). The inhibitory potencies of 11 lactones were also tested. The
simple  lactone  ring  structures  were  very  weak  inhibitors, -caprolactone being the least
potent (IC50 value =  28  mM).  An increase  in  the  length of  side  chain in  lactone correlated
with an increase in the inhibitory potency.
The inhibition by 4-benzylpyridine (BP), 4-(4-chlorobenzyl)pyridine (CBP) and 4-(4-
nitrobenzyl)pyridine (NBP) was studied in more detail due to their high potency (Figure
14). According to these experiments they all are competitive inhibitors for deethylation of
7-ethoxy-4-trifluoromethylcoumarin by CYP2B6 since the apparent Vmax was not affected
and the apparent Km increased  in  the  presence  of  these  compounds.  The  apparent  Km
values correlated linearly and significantly with the concentration of inhibitors. According
to this analysis, a Kic value of 0.15 μM (0.01-0.67 μM 95% confidence interval) was obtained
for BP, 0.002 μM (0-0.11 μM) for CBP and 0.04 μM (0-0.10 μM) for NBP.
Figure 14. Competitive  inhibition  of  CYP2B6  by  4-benzylpyridine  (BP)  (A),  4-(4-
chlorobenzyl)pyridine (CBP) (B) and 4-(4-nitrobenzyl)pyridine (NBP) (C). 7-ethoxy-4-
trifluoromethylcoumarin deethylation to 7-hydroxy-4-trifluoromethylcoumarin via recombinant
CYP2B6 was inhibited at different concentrations of the substrate and the inhibitors. The upper
panels show non-linear regression analysis of one out of 3-5 experiments with each inhibitor.
The lower panels show the effect of the inhibitor concentrations on the apparent Km values. The
Km values were obtained from experiments shown in the upper panels. The Vmax value was not
affected by the inhibitor concentration.
7.3.2 The final CoMFA model
Forty-one compounds listed in Table 13 were analyzed using the CoMFA method
(including the compounds used in the initial CoMFA model).  The created CoMFA model
was  of  high  quality  with  the  following  statistical  values  with  2  components:  q2=0.71,
SPRESS=0.64, r2=0.85, predictive r2=0.80 (Figure 15). The CYP2B6 CoMFA model is
represented as 3D contour maps with CBP as the reference structure (Figure 16).  Red and
green  maps  represent  areas  where  more  negative  partial  charge  and  bulkier  groups
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increase inhibitory potency, respectively. Blue and yellow maps represent areas where
more negative partial charge and bulkier groups decrease inhibition potency, respectively.
The  sterically  favoured  green  area  was  located  around  substitution  at  carbon  4  of  the
benzyl ring of benzylpyridine in the CoMFA model. A broad partial negative charge near
to the nitrogen atom and above and below the plane of the benzyl ring tended to increase
the inhibitory potency.
Figure 15. Plot  for  the  training  set  (actual/predicted  IC50 values)  of  the  CoMFA  model  (r2 =
0.85).
Figure 16. Colour contour maps of final CYP2B6 CoMFA model. Red and green represent areas
where more negative partial charge and bulkier groups increase inhibition potency,
respectively. Blue and yellow represent areas where more negative partial charge and bulkier
groups decrease inhibition potency, respectively. The reference structure is 4-(4-
chlorobenzyl)pyridine (CBP).
61
The prediction power of the CoMFA model was evaluated by estimating pIC50 values for
an  external  test  set  of  seven  compounds  (Table  14).  Two  of  these  compounds  are  known
substrates of CYP2B6 (selegiline and bupropion) and one is an inhibitor of this enzyme
(ThioTEPA). Four compounds were chosen on the basis that they possess structural
similarities to compounds in the training set but also contain features that differ from the
training set compounds (piperonylalcohol, 4-chlorobenzylamine, p-dimethylamino-
benzaldehyde and anisalcohol). As summarised in Table 14, the predictions of pIC50 values
for the external test set of molecules agreed well with the actual values. This is evidence
that the created CoMFA exhibits a high predictive power.
Table 14. Validation of CYP2B6 model.
pIC50 (M)
Compound Experimental Predicted Residual
Selegiline 5.41 5.33 0.08
ThioTEPA 5.00 4.3 0.70
Piperonylalcohol 4.70 4.1 0.60
Bupropion 4.55 4.23 0.32
4-Chlorobenzylamine 4.43 4.1 0.33
p-Dimethylamino-
benzaldehyde 3.96 3.8 0.16
Anisalcohol 2.85 3.36 0.51
7.3.3 CYP2B6 selectivity
The CYP selectivity of the three most potent inhibitors, BP, CBP, and NBP were further
characterized using the CYP2B6 selective bupropion as the substrate and human liver
microsomes as the enzyme source. The IC50 values for the CYP2B6 mediated bupropion
hydroxylation reaction were 0.02, 0.03 and 0.03 μM for CBP, NBP and BP, respectively
(Table 15). No changes of IC50 values were observed with any of these three inhibitors
when the experiments were carried out to reveal mechanism based (suicide) inhibition.
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With CBP and BP, the IC50 values  with  other  CYPs were  >  1  μM. The next  sensitive  CYP
form for CBP and BP inhibition was CYP1A2 with IC50 values  of  3.8  μM  and  1.2  μM,
respectively. In addition to inhibiting CYP2B6, NBP was also a potent inhibitor of CYP1A2
with  an  IC50 value of 0.02 μM (Table 15). At a 0.1 μM concentration of CBP, complete
inhibition of CYP2B6 activity was observed.  At this concentration, CBP did not affect any
other CYP related activities, and less than 20% inhibition of CYP1A2, CYP2C9 and CYP2E1
was observed at 1.0 μM CBP (Figure 17A).  Both NBP and BP were less selective, inhibiting
also CYP1A2 at both 0.1 and 1.0 μM (Figure 17B-C).
Table 15. IC50 values  of  CBP,  NBP  and  BP  on  CYP-specific  model  activities  in  human  liver
microsomes in vitro. Mechanism-based inhibition experiments for ethoxycoumarin O-
deethylation (multiple CYPs) and bupropion hydroxylation (CYP2B6) are also presented (2 min /
15 min pre-incubation).  Substrate concentrations for each model reaction in parenthesis.
IC50 (M)
CYP Substrate CBP NBP BP
Multiple 7-Ethoxycoumarin (10 	M) 7.8 / 7.8 0.05 / 0.06 2.8 / 2.8
1A2 7-Ethoxyresorufin (1 	M) 3.8 0.02 1.2
2A6 Coumarin (10 	M) 31.3 24.3 3.0
2B6 Bupropion (50 	M) 0.02 / 0.02 0.03 / 0.025 0.03 / 0.02
2C8 Amodiaquine (30 μM) > 100 > 100 > 100
2C9 Tolbutamide (200 	M) 5.4 6.8 7.2
2C19 Omeprazole (40 	M) 24.0 31.0 64.0
2D6 Dextromethorphan (10 	M) 17.5 13.3 5.1
2E1 Chlorzoxazone (100 	M) > 100 3.8 8.5
3A4 Midazolam (10μM) > 100 > 100 > 100
3A4 Testosterone (100 μM) > 100 > 100 > 100
3A4 Omeprazole (40 μM) > 100 > 100 > 100
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Figure 17. CYP inhibition selectivity of 4-(4-chlorobenzyl)pyridine (CBP) (A), 4-(4-
nitrobenzyl)pyridine (NBP) (B), and 4-benzylpyridine (BP) (C). CYP screen was carried out
using CYP specific substrates and human liver microsomes as the enzyme source.
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 7.4 Discussion
The main achievement of this study was to find two novel potent and selective inhibitors
of CYP2B6: CBP and BP. For this purpose the inhibition potencies of 41 compounds were
determined and a comprehensive 3D-QSAR (CoMFA) model was created with this data
set. In this way a precise view of the key molecular characteristics of CYP2B6 inhibitors
were obtained. The prediction power of this CoMFA model was evaluated by estimating
the pIC50 values  for  an  external  test  set  of  compounds.  The  CoMFA  model  yielded  novel
structural information about CYP2B6 inhibitors. The developed model accurately
predicted the inhibitory potencies of several structurally unrelated compounds.
An  important  aim  of  this  study  was  to  find  new  potent  and  selective  inhibitors  of  the
CYP2B6 enzyme. Ticlopidine is a potent mechanism-based inhibitor of CYP2B6 (IC50 value
= 0.32 μM), but it is also an inhibitor of CYP2C19 and it also impairs activities associated
with CYP1A2 and CYP2D6 (Ha-Duong et al. 2001; Richter et al. 2004; Turpeinen et al.
2004). ThioTEPA has been shown to be a very selective CYP2B6 inhibitor, but it is not as
potent as ticlopidine (Rae et al. 2002; Turpeinen et al. 2004). In this study we demonstrated
that CoMFA modelling can be used to identify new inhibitors. Three novel potent
inhibitors  were  found:  CBP,  NBP,  and  BP,  all  displaying  an  IC50 value of less than 1 μM.
CBP was the most selective inhibitor. It was 190 times more potent towards CYP2B6 than
towards the next sensitive form, namely CYP1A2. For BP, the next sensitive CYP form was
also CYP1A2, but the difference in potency was only 40-fold. Therefore, the chloro
substituent  in  the  benzyl  ring  in  CBP  must  influence  the  selectivity.  In  addition  to
inhibiting CYP2B6, NBP was also a potent inhibitor of CYP1A2. The NO2 group in the NBP
benzyl ring maybe the reason for its inhibitory properties. Mechanism-based enzyme
inhibition, by definition, requires metabolism of a substrate into a reactive intermediatethat
can bind to the enzyme irreversibly, resulting in the loss of enzyme activity (Kent et al.
2001). Ticlopidine is a mechanism-based inhibitor and its structure bears resemblances to
these new potent molecules. However, none of the three new compounds act as a
mechanism-based inhibitor.
The substrates of CYP2B6 are usually non-planar molecules, neutral or weakly basic,
fairly lipophilic with one or two hydrogen bond acceptors (Lewis, 2000). CYP2B6 has been
studied using homology modelling, protein docking and molecular dynamics approaches
(de Graaf et al. 2005). The 3D-QSAR approach is mostly used i.e. descriptors of essential
functional groups and topologies of the molecules are superimposed. Ekins et al. (1999b)
published two different 3D-QSAR models based on 16 CYP2B6 substrates. A
pharmacophore model was built using the program Catalyst, which was comparedwith a
partial least-squares (PLS) model using molecular surface-weighted holistic invariant
molecular (MS-WHIM) descriptors. The pharmacophore model obtained with Catalyst
consisted of three hydrophobes and one hydrogen bond acceptor region. The cross-
validated PLS MS-WHIM model gave a good q2 value of 0.607. Molecular size, positive
electrostatic potential, hydrogen bonding acceptor capacity, and hydrophobicity were
found to be the most relevant descriptors for the model. Wang and Halpert (2002)
published a homology model of CYP2B6 based on the crystal structure of CYP2C5. Also
3D-QSAR models were generated for 16 structurally diverse CYP2B6 substrates with
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Catalyst. Both include two hydrophobes and one hydrogen bond acceptor. The
pharmacophores were  combined with the  CYP2B6 model  by docking the  substrates in the
active site of CYP2B6 and the pharmacophores were used to  predict  the Km value for test
set molecules in conjunction with the CYP2B6 model.
To our knowledge there are no reports on the application of pharmacophore or QSAR
techniques in order to find new inhibitors or in order to predict the inhibitory potency of
compounds. The models described in the previous studies are based on the Km values
obtained from the literature and were based on a limited number of structurally diverse
compounds. The model presented here is based on large training set which was generated
with internally fully consistent methods. The results in our present 3D-QSAR model are
consistent with previous studies with the CYP2B6 enzyme since the importance of the
hydrophobic and electronic characteristic in the binding of inhibitors was demonstrated. In
the present study, both electrostatic and steric interactions were found to account for the
differences in inhibitory potencies. In CoMFA, electrostatic fields described the areas
where hydrogen bond acceptors or donors should be located in an inhibitor. The
significance of hydrophobicity for inhibitory potency was evident in the CoMFA steric
fields. The final CoMFA model pinpointed the location of the partial negative charge that
increases  the  inhibition  potency.  In  practice,  an  acceptor  atom  correctly  located  in  the
structure yields a more potent inhibitor. The CoMFA model also predicted accurately the
inhibitory potencies of structurally diverse compounds. The predictions for selegiline,
bupropion, 4-chlorobenzylamine and p-dimethylamino-benzaldehyde were very
successful, because the residuals between predicted and tested pIC50 values were 0.08 - 0.33
log units.
The CoMFA electrostatic and steric fields of CYP2B6 are consistent with the structure of
benzylpyridine, which contains the optimal steric, hydrophobic, and acceptor features. In
particular the benzyl structure and nitrogen acceptor atom render benzylpyridines more
potent inhibitors than e.g. lactones. It is interesting to compare the structural features of
ticlopidine and CBP, since these two compounds act via different inhibitory mechanisms.
Figure 18 shows the electrostatic fields for these two structures. The red colour in the
colour contour map of electrostatic fields means that this region has a partial negative
charge, whereas the blue colour describes a partial positive charge. The most notable
difference between these two structures is that CBP includes a partial negative region near
to the electronegative chlorine atom in the benzyl ring. Also the nitrogen acceptor atom
and the sulphur atom in ticlopidine exhibited a partial negative charge in the colour
contour map.
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Figure 18. Electrostatic fields and 2D structures of 4-(4-chlorobenzyl)pyridine (CBP) (left) and
ticlopidine (right). The electrostatic map are shown in red and blue areas in which more
negative charge increase and decrease inhibition potency, respectively.
In conclusion, the CYP2B6 CoMFA model was created which revealed the key molecular
characteristics of inhibitors of the CYP2B6 enzyme. Three novel potent inhibitors were
discovered. Of these, especially CBP was very potent and selective. Thus, CBP is a suitable
agent for in vitro studies directed at defining the relative contribution of CYP2B6 in the
metabolism of chemical compounds, including novel drugs.
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8 Inhibition studies and 3D-QSAR of CYP2E1
Inhibitors 4
Abstract: CYP2E1 is an important enzyme oxidizing ethanol as well as several drugs and
other xenobiotics in the human liver. We determined the inhibition potency of structurally
diverse compounds against human CYP2E1, and analyzed their interactions with the
enzyme active site by molecular docking and 3D-QSAR approaches. The IC50 values for the
tested compounds varied from 1.4 
M for -undecanolactone to over 46 mM for glycerol.
This data set was used to create a comparative molecular field analysis (CoMFA) model.
The most important interactions for binding of inhibitors were identified by docking and
key features for inhibitors were characterized via the COMFA model. Since the active site
of CYP2E1 is flexible, long chain lactones and alkyl alcohols fitted best into the larger open
form while the other compounds fitted better in the smaller closed form of the active site.
Electrostatic interactions near the Thr303 residue proved to be important for inhibition of the
enzyme  activity.  Thus,  docking  analysis  and  the  predictive  CoMFA  model  proved  to  be
efficient tools for revealing interactions between inhibiting compounds and CYP2E1. These
approaches can be used to analyze CYP2E1-mediated metabolism and drug interactions in
the development of new chemical entities.
Martikainen LE, Rahnasto-Rilla M, Neshybova S, Lahtela-Kakkonen M, Raunio H and Juvonen RO. Interactions of
inhibitor molecules with the human CYP2E1 enzyme active site. Manuscript
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8.1 Introduction
CYP2E1 is an important member of the cytochrome P450 (CYP) enzyme superfamily.
Although several variant alleles of the human CYP2E1 gene have been discovered, none of
these totally abolish the activity of the enzyme, suggesting that the enzyme possesses some
perhaps many, crucial endogenous properties (Ingelman-Sundberg, 2004b). In addition to
ethanol, CYP2E1 catalyzes also the metabolism of a wide variety of endogenous
substances.  Although CYP2E1 does not metabolize as many different drugs as some other
CYP  enzymes  e.g.  CYP2D6  or  CYP3A4,  it  is  known  to  be  involved  in  the  metabolism  of
several commonly used drugs such as paracetamol and chlorzoxazone (Rendic, 2002). In
general, the majority of CYP2E1 substrates are neutral, small molecular weight compounds
with relatively low log P (octanol/water partition coefficient) values (Anzenbacher and
Anzenbacherova, 2001). To date a number of CYP2E1 inhibitors have been described, but
unfortunately, they are mostly not selective (Rendic, 2002; Khojasteh et al. 2011)). These
inhibitors include the metabolite of disulfiram, diethyldithiocarbamate (Pratt-Hyatt et al.
2010), dilinoleylphosphatidylcholine, the major component of polyunsaturated
phosphatidylcholines from soy beans (Aleynik and Lieber, 2001), and diallylsulphide, a
mechanism-based inhibitor found in Allium vegetables (Loizou and Cocker, 2001).
The structures of the human CYP2E1 protein complexed with indazole and 4-
methylpyrazole have been solved (Porubsky et al. 2008). Porubsky and co-workers have
also recently co-crystallized CYP2E1 with -imidazolyl-octanoic fatty acid, -imidazolyl-
decanoid fatty acid, and -imidazolyl-dodecanoid fatty acid (Porubsky et al. 2010) and
DeVore and co-workers reported a CYP2E1 structure complexed with pilocarpine (Devore
et al. 2011). To date QSAR studies of CYP2E1 have been carried out with limited number of
structural analogues or with data obtained from different studies in the literature protein
(Wang et al. 1995; Lewis et al. 2000; Lewis et al. 2003a; Lewis et al. 2003b; Park and Harris,
2003; Spatzenegger et al. 2003; Ohashi et al. 2005; Yamazoe  et al. 2011; Wu et al. 2011).
In this study we established a convenient fluorometric multiwell plate assay to measure
inhibition  of  CYP2E1.  Using  the  data  generated  with  this  method,  the  aims  of  this  study
were: (1) to determine the inhibition potency of a large set of compounds against human
CYP2E1 and to create a new inhibition structure-activity database and (2) to analyse the
interactions between these inhibiting compounds and the CYP2E1 active site by molecular
docking and 3D-QSAR methods.
8.2 Materials and methods
The materials and general methods used are described in Chapter 4.
8.2.1 Determination of inhibition potency
The 7-methoxy-4-trifluoromethylcoumarin (MFC) O-demethylation activity assay is based
on the detection of fluorescence emitted by its metabolite 7-hydroxy-4-
trifluoromethylcoumarin (HFC). The incubations were performed in 96-well plates
(Chapter 4). MFC and the inhibitors were dissolved into water to prevent all disturbing
effects of organic solvents.
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8.2.2 Protein structure of CYP2E1
Two crystal structures of CYP2E1 were obtained from the Protein Data Bank (PDB)
database; the one co-crystallized with omega-imidazolyl octanoid acid (PDB: 3KOH) which
represents the open form, and the one co-crystallized with indazole (PDB: 3E6I),
representing the closed form of crystallized CYP2E1 protein. The quality of the structures
was assessed using the internal evaluation program PROCHECK (Laskowski et al. 1993).
The minimisation technique was used to refine the structures of CYP2E1, as previously
described (Rahnasto et al. 2011).
8.2.3 Molecular docking and CoMFA model
To create the CoMFA model (Chapter 4), the training set of the inhibitors was aligned by
docking the  9  compounds to  the  open form and 29  compounds to  the  closed form of  the
active site of the enzyme. Only structurally similar molecules (alkyl alcohols, lactones,
phenols/aromatic alcohols, quinolines and other compounds) were included in the training
set (n=32) or the test set (n=6) (Table 16). Molecules with IC50 values of >1000 μM are not
considered as inhibitors (White, 2000) and were omitted from the model. To achieve a
sufficiently homogeneous training set, all structurally very different molecules (N,N-
diethyldithiocarbamate, paracetamol and fluoxetine) were omitted from the training set.
The tested lactone derivatives were racemates and the S-(-)-enantiomers were used for the
model.
For docking the genetic optimization for ligand docking (GOLD) method (v.3.2) (Jones
et al. 1997, Verdonk et al. 2003) was used with the metal coordination parameters of the
ChemScore (Kirton et al. 2005). GOLD is a docking program that evaluates solutions of
conformers at the protein active site using scoring functions to estimate changes in free
energy  (	G)  during  binding.  The  GOLD  program  produced  different  possible  docking
poses  for  each  inhibitor,  which  were  then  ranked  based  on  a  scoring  function  (either
ChemScore or the CScore (Tripos Associates) consensus scoring ranking values) that
estimate the free energy change during binding.
8.3 Results
8.3.1 Inhibition of CYP2E1
The IC50 values of 47 compounds were determined based on their ability to inhibit
oxidation by CYP2E1 of MFC to HFC (Table 16). Recombinant human CYP2E1 was used as
the enzyme source to exclude any interference from other CYP forms. The effects of the
amount of CYP2E1 enzyme and incubation time on the oxidation of MFC to HFC were
determined. The fluorescence increased linearly with 0.5 – 1.5 pmol CYP2E1 for 40 min at
10 μM MFC concentration (data not shown). The IC50 value for each compound was
estimated at 10 μM MFC in constant conditions using seven different concentrations of
each inhibitor. Figure 19 presents an example of concentration dependent inhibition of the
enzyme activity by two structurally similar compounds.
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Figure 19. Inhibition  of  CYP2E1  activity  by  2-naphtol  () and 2-hydroxy-methyl-naphthalene
().  Inhibition  of  MFC  (10  μM)  oxidation  to  HFC  by  recombinant  human  CYP2E1  was
determined.
Overall,  the  IC50 values varied from 1.4 μM for -undecanolactone to 46 mM for
glycerol.  With  primary  alcohols  the  inhibition  potency  depended  on  the  length  of  the
hydrocarbon chain, as the IC50 decreased from methanol to 1-pentanol (Figure 20A). The
position of the hydroxyl group was also important, as the IC50 of 2-butanol was ~3 times
higher than that of 1-butanol where as the IC50 of 1-propanol was also lower than that of 2-
propanol. Interestingly, the IC50 of acetone was 16 times higher than that of 2-propanol,
indicating that a carbonyl oxygen in the hydrocarbon chain decreased inhibition potency.
The inhibitory potency of some non-alcohol solvents was also determined (Table 16).
Acetonitrile was the weakest inhibitor of the tested solvents. The IC50 values of acetone and
DMSO were practically the same (150 μM and 170 μM, respectively). Several compounds
containing a lactone ring were included in the analysis (Table 16). The weakest lactone-
type inhibitor was 
-caprolactone (IC50 51  μM),  and  the  most  potent  was  -
undecanolactone (IC50 1.4 μM). The IC50 decreased when the length of the alkyl side-chain
increased in position 5 of -lactones, however, -dodecanolactone was not more potent
than undecanolactone (Figure 20B). A total of 20 aromatic compounds were also examined
(Table 16). Some aromatic compounds were quite potent CYP2E1 inhibitors with 2-
naphthol, 1-naphthol and 2-methoxynaphthalene being the most potent. The IC50 values of
quinolines varied from 7.6 μM of 3-methylquinoline to 48 μM of 2,6-dimethylquinoline
indicating that  both the  number  and the  position of  methyl  substitutions  affect  inhibition
potency. The known CYP2E1 ligands N,N-diethyldithiocarbamate, paracetamol and
fluoxetine displayed IC50 values of 4.5 μM, 490 μM and 490 μM, respectively.
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Figure 20. Effect  of  size  of  primary  alcohols  and  -lactones  on  inhibition  potency  against
CYP2E1 activity. Panel A illustrates inhibition of MFC (10 μM) oxidation by methanol, ethanol,
1-propanol, 1-butanol and 1-pentanol, and panel B inhibition by -valerolactone, -
caprolactone, -heptalactone, -undecanolactones and -dodecanolactone.
Table 16. IC50 values of compounds towards CYP2E1
Alcohols IC50 (μM)
1-Pentanol 2.0a
1-Butanol 2.2a
2-Butanol 6.0a
1-Propanol 8.5b
2-Propanol 9.2a
Ethanol 35b
Methanol 1900
Glycerol 46000
Non-alcohol solvents IC50 (μM)
Acetone 150a
(Table continues)
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Table 16 (continued)
DMSO 170a
Formaldehyde 560
Acetonitrile 6000
Lactones IC50 (μM)
-Undecanolactone 1.4b
-Decanolactone 3.8a
-Dodecanolactone 3.9a
-Valerolactone 8.9a
4,6-Dimethyl--pyrone 14 a
-Heptalactone 19 a
-Valerolactone 23 a
-Caprolactone 25 a
4-Methoxy-2(5H)furanone 26 a
(Table continues)
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Table 16 (continued)
-Hexalactone 35 b
-Caprolactone 51 a
Aromatic compounds IC50 (μM)
2-Naphthol 1.8 a
1-Naphthol 1.9 a
2-Methoxynaphthalene 2.0 a
2-(p-Tolyl)-ethylamine 4.0 a
Butylbenzene 5.5 a
Indan 5.8 a
3-Methylquinoline 7.6 a
2,3-Dihydrobenzofuran-5-
carboxaldehyde
7.7 a
(Table continues)
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Table 16 (continued)
2,3-Dihydrobenzofuran 9.1 a
-Tetralone 9.1 a
Chlorzoxazone 9.2 a
2-Hydroxy-methyl-
naphthalene
10 a
3-Methylisoquinoline 15 a
Quinaldine 21 a
2,7-Dimethylquinoline 24 a
Pyridine 36 a
2,6-Dimethylquinoline 48 b
2-Methylbenzofuran 50 b
Paracetamol 490
(Table continues)
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Table 16 (continued)
Other compounds IC50 (μM)
N,N-Diethyldithiocarbamate 4.5
Pyrazole 20 a
Fluoxetine 490
Caffeine 5100
Theophylline 12000
a Training set molecules
b Test set molecules
8.3.2 Docking of the training set molecules
The  cavity  of  CYP2E1  above  I  helix  interacts  with  the  inhibiting  compounds  and  is
connected via a channel to the protein surface. A single amino acid, Phe298, can close (PDB
ID: 3E6I) or open (PDB ID: KOH) the connection between this cavity and the channel.
Therefore the volume of the active site increased in the open form in comparison to the
closed one. Both of these two forms were used in the docking studies, because the
orientation of the studied molecules in the active site depended on the structural form of
the crystal structure used. These two different crystal structures (open and closed forms of
the active site) took into account the flexibility of CYP2E1 protein. The selection of the
docking  orientations  was  based  on  the  ranked  values  of  the  scoring  function.  First  all
molecules  were  docked  into  both  open  and  closed  forms.  Then  the  most  favourable
orientation of an inhibitor in the active site was selected for the alignment and construction
of  the  CoMFA  model  (Figure  21A).  All  of  the  alkyl  alcohols  coordinated  towards  the
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pyridine ring of heme (Figure 21B). Most of the lactones (Figure 21C), phenols/aromatic
alcohols (Figure 21D) and solvents such as DMSO and acetone formed a hydrogen bond
with the Thr303 residue. The long-chain lactones were orientated in the same way as the
fatty acids in 3E61 crystal and formed a hydrogen bond with the Asn206 residue  (Figure
21C).
Figure 21. Docking orientation of inhibitors in the active site of human CYP2E1. The open form
(blue)  and  the  closed  form (magenta)  of  the  active  site  of  the  CYP2E1  are  shown.  Hydrogen
bonds are shown by dashed line. The reference molecules are: (A) all inhibitors overlaid; (B) 1-
pentanol (green) and 2-butanol (red); (C) -undecanolactone (green) and -valerolactone
(red); (D) 2-naphthol.
8.3.3 CoMFA model
Thirty two structurally similar compounds were included in the CoMFA training set (Table
1). The created CoMFA model with four components was of high quality, as the cross
validated q2 was 0.62, SPRESS was 0.32 and the correlation coefficient (r2) was 0.96. A
progressive scrambling test slope (dq2/dryy2) of more than 1.1 can lead to overfitting.
Therefore, the number of components in the final model was chosen so that the slope was <
1.1 (dq2/dryy2=0.9).
Six compounds structurally similar to the training set molecules were included in the
test set. The model accurately predicted the inhibitory potencies (pIC50) of the test set
compounds, as the correlation coefficient of the prediction was 0.83 (Figure 22). The
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inhibitory potency of the known CYP2E1 substrates paracetamol and fluoxetine and the
inhibitor N,N-diethyldithiocarbamate was also predicted. The model predicted correctly
the inhibition potency of N,N-diethyldithiocarbamate but not that of paracetamol and
fluoxetine (data not shown). The CYP2E1 CoMFA model is shown as 3D contour maps in
Figure 23 with 2-naphthol as the reference structure. In the red and green areas, a more
negative partial charge and bulkier groups increase inhibition potency, respectively.
Figure 22. Plot  for  the  training  set  ()  and  test  set  () (actual/predicted IC50 values) of the
CoMFA model (r2pred = 0.83).
Figure 23. Colour  contour  maps  of  CYP2E1  CoMFA  model.  The  reference  structure  is  2-
naphthol. Red and green represent areas where more negative partial charge and bulkier
groups increase inhibition potency,  respectively.  Blue and yellow represent areas where more
negative partial charge and bulkier groups decrease inhibition potency, respectively.
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In the blue and yellow areas, a more negative partial charge and bulkier groups decrease
inhibition potency, respectively. In the CYP2E1 CoMFA model, electrostatic interactions
(red/blue contours) near the Thr303 residue proved to be important for inhibition. Sterically
favoured (green) regions surrounded the active site cavity near Phe116, Asp295 and Phe298.
8.4 Discussion
In this study, the IC50 values of 47 compounds were determined against human
recombinant CYP2E1 enzyme by a convenient multiwell plate assay. A comprehensive
inhibition data set containing alcohols, other solvents, lactones and small molecular weight
aromatic compounds was created for this enzyme. Molecular docking and a predictive 3D-
QSAR (CoMFA) analysis revealed that CYP2E1 can interact with these compounds either
in the open or in the closed form. These analyses are in good agreement with the data from
crystallized CYP2E1 and indicate that electrostatic interactions near the Thr303 residue are
important for the interaction between inhibitor molecules and the enzyme active site.
Alcohols  are  well  known substrates  and also  inhibitors  of  CYP2E1 (Bolt  et  al.  2003).  In
this study, the IC50 values of series of primary alcohols and secondary alcohols were
determined. Secondary alcohols were less potent inhibitors than the corresponding
primary alcohols. The IC50 values depended on the length of the hydrocarbon chain, as it
decreased with the length of the carbon chain from methanol (IC50 1.9 mM) to pentanol
(IC50 2.0 μM). These findings are in good agreement with the study of Wang et al. (1995).
They monitored the inhibitory effects of alcohols and acids on CYP2E1-specific oxidation
of N-nitrosodimethylamine. An increase in the alcohol carbon chain length up to seven
carbons  yielded  a  binding  energy  of  0.28  kcal/mol  CH2.  Acetone  is  an  inducer  and  a
substrate of CYP2E1 (Song et al. 1989; Bondoc et al. 1999). This study demonstrates that it is
also a CYP2E1 inhibitor (IC50 150  μM).  DMSO,  containing  a  sulphur  atom  instead  of
carbon, has about the same IC50 value (170 μM). In contrast, the carbonyl oxygen of acetone
decreases the potency, i.e. 2-propanol is 16 times more potent than acetone.
Several QSAR approaches have been applied to the CYP2E1 protein (Wang et al. 1995;
Lewis et al. 2000; Lewis et al. 2003a; Lewis et al. 2003b; Park and Harris 2003; Spatzenegger
et al. 2003; Ohashi et al. 2005; Yamazoe et al. 2011; Wu et al. 2011). In addition several
crystal structures of CYP2E1 protein has been published (Porubsky et al. 2008; Porubsky et
al. 2010; Devore et al. 2011). These structures have emphasized that the CYP2E1 protein is
very  flexible.  The  CYP2E1  active  site  is  in  the  closed  form  with  the  low  molecular  mass
ligands indazole or 4-methylpyrazole, and in the open form with high molecular mass
ligands, such as fatty acid substrate analogs of various chain lengths (Porubsky et al. 2008;
Porubsky et al. 2010; Devore et al. 2011). Our docking results also showed that low
molecular  mass  ligands  such  as  short-chain  lactones  were  orientated  differently  in  the
active site compared with high molecular mass ligands such as long-chain lactones.
Hydrogen bonding,  stacking and desolvation of the heme environment are thought
to play important roles in CYP2E1 substrate binding affinity (Lewis et al. 2003a). The
present docking analysis showed that the active site of CYP2E1 consists of two hydrogen-
bonding sites (Thr303 and  Asn206).  The  interaction  of  larger  inhibitors  with  Asn206 was
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important only in the open form of the active site. Most of the lactones, aromatic alcohols
and  solvents  such  as  DMSO  and  acetone  formed  a  hydrogen  bond  with  Thr303, which is
seen also in the crystal structure with imidazole and 4-methylpyrazole. Mutational studies
have identified Thr303 as important distal binding site feature (Fukuda et al. 1993; Imai et al.
1994; Moreno et al. 2001).
The created CoMFA model supported the docking results. The CYP2E1 CoMFA fields
showed that hydrogen-bond acceptor/donor interactions are important near Thr303. The
sterically favoured and disfavoured regions provided indications about the optimal
volume and shape of a potent inhibitor.
The created CoMFA model supported the docking results. The CYP2E1 CoMFA fields
showed that hydrogen-bond acceptor/donor interactions are important near the Thr303
residue. The sterically favoured and disfavoured regions provided indications about the
optimal volume and shape of a potent inhibitor. The predictive power of a CoMFA model
is highly dependent on the training and test set molecules having similar chemical features
(Höltje, 2003). The predictive power of this CYP2E1 CoMFA model was ascertained by
omitting the few structurally different compounds from the analysis. Consequently, the
current model was able to predict the inhibition potency of compounds possessing similar
chemical features as the training set compounds. The model did not predict accurately the
inhibition potency of the CYP2E1 substrates paracetamol and fluoxetine. These molecules
were structurally very different from the training set compounds and therefore the model
was not predictive for them. In addition, paracetamol and fluoxetine are CYP2E1
substrates rather than inhibitors and may possess different binding modes with the
enzyme active site.
In  conclusion,  a  sensitive  and  rapid  assay  to  measure  IC50 values  of  compounds  for
CYP2E1 was established and inhibition potencies of 47 compounds were determined. The
molecular docking and CoMFA analyses revealed the most important interactions of
inhibitors with the CYP2E1 active site. The CoMFA model accurately predicted the
inhibition potency of a test set of molecules. Thus, the combination of CoMFA and docking
analyses is a good approach to rationally design potent and selective inhibitors of CYP2E1.
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9 General discussion
The  discovery  and  development  of  drugs  demands  huge  investments,  much  labour  and
technological  expertise  (Dimasi  et  al.  2003).  The  process  of  drug  discovery  and
development involves the identification of leads, synthesis, characterization, screening,
toxicological tests, in the route towards a of randomised clinical trial program. This
discovery  and  development  process  can  take  more  than  a  decade  before  NCE  ultimately
receives marketing authorisation (Figure 24). In most countries, there is some sort of formal
drug approval process. The main points are similar regardless of the country, although the
actual  regulation  process  may  vary.  In  Europe,  EMA  is  responsible  for  the  scientific
evaluation of applications for European marketing authorisations for both human and
veterinary medicines. In the centralised procedure, companies submit a single marketing
authorisation application to the EMA. Once granted by the European Commission, a
centralised marketing authorisation is valid in all European Union (EU) and EEA-EFTA
states (Iceland, Liechtenstein and Norway). Generally, documentation is required about
proof of safety and efficacy as well as the high quality of the product.
Poor pharmacokinetic properties, severe ADRs, major DDIs, animal toxicity or lack of
efficacy can lead to the withdrawal of NCE from clinical trials. The evaluation of ADMET
profiles of drug candidates during pre-clinical development represents one of the crucial
parts of the drug discovery process. Efficient profiling operations are now run in parallel to
potency screening during lead optimization. In vitro assays are used during early drug
development and high-throughput ADMET screens are available. The advantage of using
in silico approaches over in vitro assays is that less investment is needed in resources, time
and technology.
Figure 24. Drug discovery and development process (modified from Ashburn and Thor, 2004).
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The  general  aim  of  this  study  was  to  develop  novel in vitro and in silico methods  to
assess the metabolic features of xenobiotics. These techniques will be further refined with
the ultimate aim of developing the capability to predict inhibition properties across the
human CYP spectrum of novel drugs and other compounds.
Comparison of in vitro tests
In the first part of the present study, three CYP in vitro inhibition screening tests were
compared: the traditional single substrate assays, the fluorescent probe method with
recombinant human CYPs, and a novel n-in-one technique (Chapter 5). The results
revealed that the three assay types yielded very similar results with the majority of tested
CYP  forms.  In  the  subsequent  studies  the  fluorescent  probe  method  was  used  for
measuring the inhibition potency. This method possesses the advantages of speed and high
throughput. Currently, LC/MS methods have evolved into effective tools for the analysis of
drug metabolism; they are fast, reliable and robust analytical means which are applicable
in various in vitro and in vivo situations (Kostiainen et al. 2003; Pelkonen et. al. 2008). This
approach offers some advantages over fluorometric assays e.g. simultaneous evaluation of
several CYP isoform activities, the high selectivity of the probe substrates for their
respective CYP enzymes and the use of clinically relevant probe substrates (Fowler and
Zhang, 2008). It also allows for the direct quantification of the marker substrate or product
(Foti et al. 2010) LC with time-of-flight (TOF) or quadrupole (Q)TOF mass spectrometers
are the instruments of choice for screening (metabolite screening and tentative
identification) and the use of TOF-MS is clearly the most time-efficient way to screen and
tentatively identify metabolites from various in vitro sources (Pelkonen et al. 2008).
Nevertheless, as LC/MS techniques require expensive instruments and highly specialized
skills,  the  much  simpler  and  cheaper  methods  such  as  fluorometric  assays  still  play  an
important role as screening methods.
CYP1A2
Three CYP enzymes were selected (CYP1A2, CYP2B6, CYP2E1) for further evaluation, and
new databanks of inhibitors were created. The inhibition potencies of large series of
chemicals were determined against these enzymes. All data used in the training sets was
generated with internally fully consistent methods. Some disubstituted naphthalene and
quinoline  derivatives  were  found  to  be  potent  inhibitors  of  CYP1A2  (Chapter  6).  The
results indicated that substitutions at the C1 position of naphthalene with hydrophobic
substituents such as halogen or methyl groups increased the inhibitory potency. The IC50
values of molecules decreased as the molecular volume of lactones and the length of alkyl
side chain increased. In addition a large steric-favoured region was located near the C7
position in the CoMFA map. This data suggests that the binding pocket of the CYP1A2
enzyme is composed of mostly hydrophobic and aromatic amino acids with the polar
amino acids for hydrogen bonding being present near to the heme centre. The created
CoMFA  model  predicted  very  accurately  the  inhibitory  potencies  of  the  test  set  of
compounds. Later the crystal structure CYP1A2 in a complex with the inhibitor -
naphthoflavone has been published (Sansen et al. 2007). The structure revealed a compact,
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closed active site cavity of CYP1A2, which can fit well with planar compounds such as -
naphthoflavone and typical small-molecular-weight CYP1A2 substrates such as
theophylline, caffeine, tizanidine, melatonin, tacrine, and clozapine. CYP1A2 substrates
generally contain planar a ring that can fit into the narrow and planar active site of the
enzyme. Thus the structure explains the substrate specificity of CYP1A2 (Zhou SF et al.
2009c).
CYP2B6
For CYP2B6, both electrostatic and steric interactions were found to account for the
differences in inhibitory potencies (Chapter 7). In CoMFA, electrostatic fields described the
areas  where  hydrogen  bond  acceptors  or  donors  need  to  be  located  in  an  inhibitor.  The
significance of hydrophobicity for inhibitory potency was evident in the CoMFA steric
fields. The CoMFA model accurately predicted the inhibitory potencies of several
structurally unrelated compounds. This study demonstrated that CoMFA modelling could
be used to identify new inhibitors.  Three novel potent inhibitors were found: CBP, NBP,
and BP, all displaying IC50 values of less than 1  μM.  Recently  the  crystal  structures  of
CYP2B6 in complex with BP and NBP were resolved (Shah et al. 2011). The crystal
structures  revealed  a  closed  active  site  comprising  amino  acid  residues  that  can  vary  the
conformation of their side chains to allow binding of diverse ligands; particularly those of
phenylalanine residues (Phe206 and Phe297 side chains, along with the movement of Phe108)
within the hydrophobic cavity. In addition, the highly conserved Ser304 may  play  an
important role in substrate binding by forming a hydrogen-bonding network near the
active site (Shah et al. 2011).
CYP2E1
For  CYP2E1,  a  sensitive  and  rapid  assay  to  measure  IC50 values  of  compounds  was
established and inhibition potencies of 47 compounds were determined and in addition to
CoMFA, molecular docking was also carried out (Chapter 8). Docking results and CoMFA
showed that CYP2E1 could interact with these inhibiting compounds either in the open or
in the closed form and that the active site of CYP2E1 consisted of two hydrogen-bonding
sites (Thr303 and Asn206). The CoMFA model predicted accurately the inhibition potency of a
test set of molecules. Several crystal structures of CYP2E1 protein have been published
(Porubsky et al 2008; Porubsky et al. 2010; Devore et al. 2011). The CYP2E1 active site is in
the  closed  form  with  the  low  molecular  mass  ligands  and  in  the  open  form  with  high
molecular mass ligands.  Furthermore, these docking results showed that low molecular
mass ligands such as short-chain lactones were orientated differently in the active site
compared with high molecular mass ligands such as long-chain lactones.
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Future perspectives
Pharmaceutical companies are currently under immense pressure to reduce the cost of
drug discovery and development. In the early phase of drug discovery and development,
in vitro HTS and in silico studies  can  be  applied  for  the  prediction  of  the  possible
involvement of CYP enzymes in the metabolism of drugs or drug candidates. These studies
could potentially make drug design more efficient, less costly and improve drug safety and
possibly replace some of the in vivo experiments.
In the future, one can foresee that in silico models  will  become  very  efficient  tools  for
predicting the structural requirements of inhibitors of CYP enzymes. In particular, the
combination of QSAR and protein models represents a potentially very powerful approach
for predicting CYP metabolism. Unfortunately, the development of in silico models is not
straightforward and there are various reasons why these models may fail. For example,
failure can be due to the poor quality of original data. Some endpoints are complex
increasing the difficulty of creating a useful model. In addition, reliable in silico-in vitro-in
vivo correlation is still very difficult because of the multiplicity of mechanisms involved.
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10 Conclusions
The main conclusions of the present study are as follows:
1. Three assay types, the traditional single substrate assays, the fluorescent probe
method with recombinant human CYPs, and a novel n-in-one technique, yielded
similar results with the majority of tested CYP forms.  The fluorescent probe assay
was  found  to  be  useful  and  suitable  for  measuring  the  inhibition  of  major  drug-
metabolizing CYP activities compared to a conventional single substrate assay.
2. For CYP1A2, CYP2B6 and CYP2E1, new inhibition structure-activity databases were
created. These were large and composed of structurally diverse compounds.
3. The created CoMFA models revealed the key molecular characteristics of inhibitors
of the CYP1A2, CYP2B6 and CYP2E1 and were also able to accurately predict the
inhibitory potencies of the test set of compounds.
4. For CYP2B6 three novel potent inhibitors were discovered, CBP, BP and NBP. CBP
is particularly a suitable inhibitor for use in in vitro screening studies.
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Cytochrome P450 (CYP) enzymes are 
important enzymes involved in drug 
metabolism. In the present study, the 
overall goal was to develop novel in 
vitro and in silico methods to assess 
the metabolic features of xenobiotics. 
In vitro high throughput screening 
and in silico studies can provide early 
prediction of the possible involve-
ment of CYP enzymes in the metabo-
lism of drugs or drug candidates. 
Therefore these studies could poten-
tially make drug design more effec-
tive, less costly and improve drug 
safety and replace some of the in vivo 
experiments.   
